pubs.acs.org/joc

Article

Atropisomeric Properties of N-Acyl/N-Sulfonyl 5H-Dibenzo[b,d]azepin-7(6H)-ones

Takuya Namba, Mayuno Hotta, Hidetsugu Tabata, Kosho Makino, Tetsuta Oshitari, Hideaki Natsugari, and Hideyo Takahashi*



ABSTRACT: The stereochemistry of *N*-acyl/*N*-sulfonyl 5*H*-dibenzo[*b*,*d*]azepin-7(6*H*)-ones (**I**, **II**) was examined in detail by freezing the conformation with a methyl group at the C-4 of dibenzoazepine. Because the two axes (axis 1, axis 2) move together concertedly, **I** and **II** exist only as a pair of enantiomers $[(a^1R, a^2R) \text{ and } (a^1S, a^2S)]$, which was confirmed by X-ray analysis of **IIBc**. It was elucidated that the amide derivatives **I** exist in equilibrium with the *E*/*Z*-amide (100:2–100:34), which means that the exocyclic bond (axis 3) is not in concert with the endocyclic axes (axis 1, axis 2). For the preparation of 5*H*-dibenzo[*b*,*d*]azepin-7(6*H*)-one, the intra-



molecular Friedel–Crafts acylation of N-(1,1')-biphenyl-2-yl-glycine derivatives was revisited. It was revealed that the electronwithdrawing property of the amino-protective group was a key to the success of seven-membered cyclization.

INTRODUCTION

Recently, we have been interested in the conformational analysis of benzo-fused seven-membered-ring nitrogen heterocycles, which are found as the scaffolds of many drugs.¹ Our continuing interest in the relationship between axial chirality and biological activity^{2,3} prompted us to examine the *N*-acyl/*N*-sulfonyl 5*H*-dibenzo[*b*,*d*]azepin-7(6*H*)-ones (**I**, **II**) (Figure 1), which were reported to have immunosuppressive effects by



Figure 1. N-Acyl 5H-dibenzo[b,d]azepin-7(6H)-ones (I) and N-sulfonyl 5H-dibenzo[b,d]azepin-7(6H)-ones (II).

inhibiting the potassium channel (Kv1.3, IK-1) of T cells.⁴ The Ca²⁺-dependent potassium channel IK-1 and the voltage-gated potassium channel Kv1.3 in human T cells play a pivotal role during cell proliferation. Thus, inhibitors of these channels could be expected to be new drug candidates for treating autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.⁵

The 5*H*-dibenzo[*b*,*d*]azepin-7(6*H*)-one moiety has dynamic axial chirality based on the sp^2-sp^2 axis arising from the biphenyl (axis 1). In addition, *N*-acylated derivatives (I) have another axial chirality around the Ar-NC(=O) (sp^2-sp^2) axis (axis 2) and *E*/*Z*-amide rotamers based on the N-C(=O) axis (axis 3). Thus, *N*-acylated derivatives (I) should exist in

(aS)/(aR) axial isomers⁶ derived from axes 1 and 2, and E/Zamide rotamers derived from axis 3. Similarly, the congener Nsulfonyl derivatives (II) were considered to have atropisomeric properties caused by the biphenyl (axis 1) and $Ar-N(SO_2)$ (axis 2). Their complex stereochemical structures are considered to constitute a key core structure of the immunosuppressive activity. Although the conformational change, i.e., ring flip, in molecules without a methyl substituent at the ortho position of the benzene ring $(R^1 = H)$ was anticipated to be too rapid for isolation of the stereoisomers at room temperature, molecules with 4-methyl $(R^1 = Me)$ were expected to freeze the conformations so that relatively stable stereoisomers could be separated. Such investigations should reveal the active structure (eutomer) exerting the inhibitory activity on the potassium channel (Kv1.3, IK-1) of T cell activity. Herein we describe a study of the conformational properties of the N-acyl/N-sulfonyl 5H-dibenzo[b,d]azepin-7(6H)-ones nucleus (I, II), and preliminary results of the blockade of the potassium channel. Through the synthesis, the intramolecular Friedel-Crafts acylation as a crucial step to provide the 5H-dibenzo [b,d] azepin-7(6H)-one nucleus was revisited. It was shown that the electron-withdrawing effect of the N-substituent of the amino acids affects the yield of cyclized compounds.

Received: March 12, 2021 **Published:** May 17, 2021





pubs.acs.org/joc

RESULTS AND DISCUSSION

Preparation of 5H-Dibenzo[*b,d*]**azepin-7(6H)-ones.** For the preparation of 5H-dibenzo[*b,d*]**azepin-7(6H)-one**, we intended to utilize the intramolecular Friedel–Crafts acylation of *N*-(1,1')-biphenyl-2-yl-glycine derivatives (1). The cyclization of the aryl amino acids appeared to be an obvious route. According to the procedure reported in a previous paper,⁴ the corresponding acid chlorides, prepared from *N*-(1,1')-biphenyl-2-yl-glycine using thionyl chloride, were treated with anhydrous aluminum chloride. However, the reaction of *N*-(1,1')-biphenyl-2-yl-glycine derivatives with an *N*-acetyl (1Aa), *N-p*-toluoyl (1Ab) provided complex mixtures (Table 1, entries 1, 2). Since further examination of the various

 Table 1. Intramolecular Friedel–Crafts Acylation of Aryl

 Amino Acids



reaction conditions was not rewarding, the pioneering work on Friedel–Crafts cyclization of aryl amino acids⁸ was reviewed. It was reported that Friedel–Crafts intramolecular acylation of aryl amino acids has little hope of succeeding because it gave a mixture of isoquinoline derivatives, oxazolonium halides, and phenanthridine derivatives as major products. Among them, Paterson and Procter reported that the *N-p*-tosylated aryl amino acid reacted to give the desired cyclic compound, although other *N*-acylated ones did not cyclize.⁹ In light of this, we focused on the amino-protective groups of the electronwithdrawing property and revisited the intramolecular Friedel–Crafts acylation of aryl amino acids.

As expected, the cyclization of N-(1,1')-biphenyl-2-ylglycine derivatives with an N-p-tosyl group (1Ac) provided the corresponding 5H-dibenzo[b,d]azepin-7(6H)-one derivative (IIAc) in 91% yield (Table 1, entry 3). Similarly, N-mesyl (1Ad), N-o-nosyl (1Ae), and N-p-nosyl (1Af) were feasible for producing N-sulfonyl derivatives (IIAd-f) (Table 1, entries 4-6). Additionally, N-trifluoroacetyl (1Ag) and N-methoxycarbonyl (1Ah) also provided *N*-acyl derivatives (IAg, IAh) in good yields (Table 1, entries 7, 8). These results indicate that the electron-withdrawing property of the amino-protecting group is very important for this ring-closing reaction. Pleased with this, we further examined the cyclization of 4-methyl-substituted derivatives (1Bc-h). Despite the steric hindrance, 4-methyl-*N*-acyl/*N*-sulfonyl 5*H*-dibenzo[*b*,*d*]azepin-7(6*H*)-ones (IIBc-h) were obtained in good yields (Table 1, entries 9–14).

Stereochemistry of N-Acyl-5H-Dibenzo[b,d]azepin-7(6H)-ones. N-Acyl 5H-dibenzo[b,d]azepin-7(6H)-ones (IA) $(R^1 = H)$ and (IB) $(R^1 = Me)$ should have chirality based on the sp^2-sp^2 axis arising from the biphenyl (axis 1). In addition, another axial chirality arising from the sp^2-sp^2 axis of the benzene-amide bond (axis 2) should exist as well as E/Zamide diastereomers around the N-C(=O) bond (axis 3). It was therefore anticipated that IA and IB exist as complicated stereoisomers. However, our preceding studies on this dibenzoazepinone nucleus revealed that axes 1 and 2 move concertedly to form the stable relative configuration.¹¹ Thus, we presumed that the configuration of the enantiomers should be (a^1R, a^2R) and (a^1S, a^2S) , respectively. Additionally, E/Zamide diastereomers around the N-C(=O) bond (axis 3) were assumed to exist. The conformational properties of IA and IB are highlighted in Figure 2.





First, the conformational properties of IAg-h ($\mathbb{R}^1 = H$) in the solution state were investigated precisely using ¹H NMR spectroscopy (Figure 3). Compounds IAg and IAh were shown to exist as an equilibrium mixture of diastereomers in solution (CDCl₃) at the ratios 100:7 [Figure 3b] and 100:30 [Figure 3c], respectively. In each spectrum, one of the two

pubs.acs.org/joc



Figure 3. ¹H NMR spectra of IAa (a), IAg (b), and IAh (c).





diastereotopic H-6 proton resonances in the major amide diastereomer is located at about 5.6 ppm (IAg) and 5.4 ppm (IAh), each 1.5 ppm, 1.3 ppm downfield from its partner, respectively. This downfield shift was also previously observed by Hassner^{12a} and Qadir et al.,^{12b} who ascribed the phenomenon to coplanarity between the exocyclic amide carbonyl bond and the equatorial proton on the adjacent carbon (C-6). Based on this anisotropic effect of the carbonyl group, we presumed that both IAg and IAh exist in the Eamide in preference to the Z-amide. It is clear that the two endocyclic axes (axes 1 and 2) move together concertedly, although the exocyclic axis (axis 3) does not move in concert with them. Viewed in this light, it was assumed that the sevenmembered ring 5*H*-dibenzo[b,d]azepin-7(6*H*)-one exists only as a pair of enantiomers $[(a^1R, a^2R) \text{ and } (a^1S, a^2S)]$ without the presence of diastereomers $[(a^1R, a^2S) \text{ and } (a^1S, a^2R)]^{11}$

In need of solid evidence for the determination of the E/Zamide stereochemistry, investigation using NOE spectra seemed promising. However, the trifluoroacetyl group in **IAg** was not observed in ¹H NMR, and the methoxy carbonyl group in **IAh** was inadequate because of the flexibility of the -O-Me bond. Thus, the *N*-acetylated compound **IAa** was prepared for this purpose from **IAg** through two steps (hydrolysis and acetylation) (Scheme 1).

IAa as well as IAg-h was shown to exist as an equilibrium mixture of E/Z-amide diastereomers in solution (CDCl₃) at the ratio 100:2 [Figure 3a]. Additionally, one of the two diastereotopic H-6 proton resonances in the major amide

diastereomer is located at about 5.7 ppm, 1.7 ppm downfield from its partner. Irradiation of the dominant CH_3 resonance of acetyl in the major amide diastereomer led to 2.65% enhancement of the 4-H proton of benzene (Scheme 1). Therefore, the preference of the *E*-amide in IAa was determined. Based on this, the preference of the *E*-amide observed in IAg and IAh was confirmed. It was also revealed that IBg-h ($\mathbb{R}^1 = Me$) showing similar spectra (see Supporting Information) preferred the *E*-amide to the *Z*-amide in solution (Table 2).

Furthermore, the following computational studies were carried out to study the conformational preferences of N-acyl 5*H*-dibenzo[b,d]azepin-7(6*H*)-ones of IAa, IAg, IAh, IBg, and IBh. First, the conformational ensembles of IAa, IAg, IAh, IBg, and IBh were generated from 2D chemical structures as the initial structures for the density functional theory (DFT) calculations. These conformations were generated and optimized with the RDKit using the universal force field (UFF) and clustered using a tolerance of 0.2 Å root-meansquare deviation. For each conformer, the Hartree–Fock (HF) calculations were carried out to obtain optimized geometries and energies at the RHF/6-31G(d) levels. For each conformer excluding atropisomers, DFT calculations were carried out to obtain optimized geometries and energies at the RB3LYP/6-31G(d) and the RmPW1PW91/6-311+G(d,p) levels. The relative energy differences of the two conformers were estimated on the basis of geometries fully optimized with mPW1PW91/6-311+G(d,p) with energy calculations with the Table 2. E/Z Equilibrium Ratio and Energy Differences of IAa, IAg, IAh, IBg, and IBh Based on ¹H NMR and DFT Calculation¹³



				Energy difference (kJ/mol)	
	\mathbb{R}^1	R ²	E/Z ratio (¹ H NMR at 296 K in CDCl ₃)	Experimental ΔG_{Tc}	Calculated (DFT) ΔG_{298}
IAa	Н	Me	100:2	9.7	10.3
IAg	Η	CF_3	100:7	6.7	7.2
IAh	Η	MeO	100:30	3.0	2.8
IBg	Me	CF_3	100:17	4.4	3.5
IBh	Me	MeO	100:34	2.7	3.0

^{*a*}Unfortunately, each E/Z-amide of N-acyl SH-dibenzo[b,d]azepin-7(6H)-ones (IAa, IAg-h, IBg-h) was not separated by HPLC at rt.

RmPW1PW91/6-311+G(d,p) in the SCRF/IEFPCM model in CHCl₃.¹³ Zero-point energy (ZPE) correction was made on the basis of the frequency calculation with the RmPW1PW91/ 6-311+G(d,p). The results are shown in Table 2. As a representative result obtained in those computational studies, the selected conformers of the E/Z-amide of IAa are illustrated in Figure 4. Others are shown in the Supporting Information.



Figure 4. Conformers of **IAa** with the $(a^{1}S, a^{2}S)$ stereochemistry and free energy difference (ΔG_{298}) calculated by the DFT method.

It was confirmed that *N*-acyl *SH*-dibenzo[*b*,*d*]azepin-7(*6H*)ones exist in the stable relative configuration of a pair of enantiomers $[(a^1R, a^2R) \text{ and } (a^1S, a^2S)]$ without the presence of diastereomers $[(a^1R, a^2S) \text{ and } (a^1S, a^2R)]$. Additionally, in each case, the *E*-amide was preferred, although the energy difference between the *E*-amide and *Z*-amide was less than 10.3 kJ/mol.

Then we investigated the physicochemical properties of (a^1R, a^2R) - and (a^1S, a^2S) -axial isomers. As mentioned above, methylene protons (H-6) in these compounds were observed as diastereotopic, meaning the presence of axial chirality. In **IAg** (R¹ = H), however, the ring inversion via rotation around the axis was too rapid for separation of the axial isomers at rt, and thus **IAg** was not separated by chiral HPLC. On the other hand, compound **IBg** with a 4-methyl substituent (R¹ = Me) was conformationally frozen and separable into the stable (a^1R, a^2R) - and (a^1S, a^2S) -isomers, and the separated isomers showed a high energy barrier to rotation $(\Delta G^{\ddagger} = 124.8 \text{ kJ/mol})$.¹⁴ Next, N-methoxycarbonyl SH-dibenzo[b,d]azepin-7(6H)-one (**IAh**) and its 4-methyl derivative (**IBh**) were investigated, and similar results were obtained. While each

enantiomer of **IAh** without the 4-methyl substituent ($\mathbb{R}^1 = \mathbf{H}$) was not separable at rt, **IBh** with the 4-methyl substituent ($\mathbb{R}^1 = \mathbf{M}e$) was separable into the stable (a^1R , a^2R)- and (a^1S , a^2S)-axial isomers, and the separated isomers showed a high energy barrier to rotation ($\Delta G^{\ddagger} = 116.0 \text{ kJ/mol}$). The physicochemical properties of **IBg** and **IBh** are shown in Table 3. As expected, the 4-methyl ($\mathbb{R}^1 = \mathbf{M}e$) substituent was helpful to freeze the conformations so that the relatively stable stereoisomers could be separated.





80 °C. Stereochemistry of N-Sulfonyl-5H-dibenzo[b,d]azepin-7(6H)-ones. The stereochemistry of the N-sulfonyl derivatives (IIA/B) was investigated next, and a general

picture of the conformational property is shown in Figure 5. Although the sulfonamide group is an important functional moiety observed in various biologically active compounds, its physicochemical properties are not as well understood as those of the amide group. Similar to N-acyl derivatives (IA/B), N-



Figure 5. Conformational property of *N*-sulfonyl-5*H*-dibenzo[*b*,*d*]-azepin-7(6*H*)-ones.

sulfonyl derivatives (IIA/B) should have chirality based on the sp²-sp² axis arising from the biphenyl (axis 1). In addition, another axial chirality arising from the benzene-sulfonamide bond should exist. Our studies have recently revealed that the atropisomeric property of the sulfonamide group is caused by the Ar-N(SO₂) axis (axis 2).^{7a,15} The planarity of the N-SO₂ arises from both the nitrogen atom possessing an sp²-like nature and the double-bond character between the S-N bond. As well as *N*-acyl derivatives (IA/B), it was anticipated that axes 1 and 2 would move together concertedly to form the stable relative configuration of (a¹R^{*}, a²R^{*}). Thus, the configuration of the enantiomers was presumed to be (a¹R, a²R) and (a¹S, a²S), respectively.

In order to elucidate how axes 1 and 2 move together concertedly to form the stable relative configuration, N-tosyl 5*H*-dibenzo [b,d] azepin-7(6*H*)-one (IIAc) ($\mathbb{R}^1 = H$) and its 4methyl derivative ($\hat{R}^1 = Me$) (IIBc) were examined. In the ¹H NMR (CDCl₃) spectra of IIAc and IIBc, they exist as a single compound, and each methylene proton (6-H) was observed as a separated sharp peak, which indicates the presence of chirality. The atropisomers of (IIAc) $(R^1 = H)$ were inseparable by chiral HPLC because the ring inversion via rotation around the axis was too rapid for separation at rt. In contrast, those of **IIBc** $(R^1 = Me)$ were sufficiently stable to be separated and isolated with chiral HPLC at rt; the separated isomers showed a high energy barrier to rotation ($\Delta G^{\ddagger} = 127.5$ kJ/mol). Each isomer has opposite $[\alpha]_D$ values: that with shorter retention time in HPLC at 96.8% ee showed $[\alpha]_{D}$ -65.8 (c 0.23, CHCl₃) and that with a longer retention time in HPLC at 96.1% ee showed $[\alpha]_{D}$ +64.9 (c 0.21, CHCl₃), confirming that they are enantiomers. As well as N-tosyl 5Hdibenzo [b,d] azepin-7(6H)-one (IIAc) (R¹ = H), the atropisomers of other N-sulfonyl derivatives (IIAd-f) $(R^1 = H)$ were inseparable by chiral HPLC. On the other hand, the presence of the atropisomers of the corresponding 4-methyl derivative (IIBc-f) ($\hat{R}^1 = Me$) was confirmed by isolating each isomer by chiral HPLC. The separated isomers showed a high energy barrier to rotation (IIBd: $\Delta G^{\ddagger} = 126.3$ kJ/mol, IIBe: ΔG^{\ddagger} = 131.6 kJ/mol, IIBf: ΔG^{\ddagger} = 131.6 kJ/mol). The physicochemical properties of IIBc-f are shown in Table 3. It is noteworthy that compounds IIBe and IIBf with the most electron-withdrawing nosyl group showed the highest energy barrier to rotation.

Fortunately, a single crystal for the X-ray crystal structure analysis of IIBc (racemate) was obtained, in which IIBc possessed the stable relative configuration of (aR, aR) and (aS, aR)aS) as expected in a unit cell (Figure 6). It was revealed that axial chirality caused by the $Ar-N(SO_2)$ axis (axis 2), which showed a rather high energy barrier ($\Delta G^{\ddagger} = 126.3 - 131.6 \text{ kJ}/$ mol), moves concertedly with the axis at the biphenyl (axis 1) to form the stable relative configuration of (aR^*, aR^*) without the presence of diastereomers (aR^*, aS^*) . Such a high energy barrier might be due to the planarity of the nitrogen atom. The sum of angles around the nitrogen atom in the >N-SO₂ moiety is 359.2° , indicating the sp²-like nature of the nitrogen atom. In addition, the bond length between N-S (0.16 nm) suggests the double-bond character of the N-S bond. While these data imply that the > N-S moiety forms a plane, it was found that the SO₂ moiety locates so as to interweave with the N-SO₂ axis: dihedral angles $\angle O^1$ -S-N-C6 and $\angle O^2$ -S-N-C4a were -44.90° and $+12.64^{\circ}$, respectively. The important point to note is that the sulfonyl (S=O) bond is not on the >N-S plane. Considering that the carbonyl (C=



Figure 6. X-ray crystal structure of **IIBc**. The structure with the $(a^{1}R, a^{2}R)$ stereochemistry was extracted from the CIF data of the racemates.

O) is on the amide (>N-C=O) plane and the N-C bond has a double-bond character due to the resonance, the doublebond character of the N-S bond without the planarity of sulfonamide (>N-S=O) is interesting. It was also found that the seven-membered ring exists in a boat-like form, the benzene ring of the tosyl moiety locates over the benzene ring of biphenyl (folded form), and they are nearly parallel to each other.

Blockade of Potassium Channel Kv1.3. We next conducted a preliminary investigation of the blockade of the potassium channel. Considering the level of activity on Kv1.3 of **IIAc** (IC₅₀ 5.8 μ M),⁴ blocking activity on the voltage-gated potassium channel Kv1.3 with 4-aminopyridine as a positive control was tested for **IIBc** using patch-clamp technology (Table 4). **IIBc** in racemic form showed a moderate level of

Table 4. Blocking Activity of IIBc at 10 μ M (Racemate and Atropisomers)

	% Inhibition ^a
IIBc	63
(+)-IIBc	14
(–)-IIBc	43
4-Aminopyridine ^b	19

 $^a\%$ inhibition values shown are the means of duplicate measurements. $^b{\rm At}$ 100 $\mu{\rm M}.$

inhibitory activity of 63% at 10 μ M when the channel was in the closed state. Hence, the separated enantiomers of (+)-**IIBc** and (-)-**IIBc** were subjected to the binding assay to examine the difference in potency between the enantiomers. Although the enantiomers and the racemate exhibited similar levels of affinity (within a 4.5-fold difference), (-)-**IIBc** showed more potent affinity than (+)-**IIBc**.

CONCLUSION

The efficient synthesis of *N*-acyl/*N*-sulfonyl *SH*-dibenzo[*b*,*d*]azepin-7(6*H*)-ones and the physicochemical properties of *N*acyl/*N*-sulfonyl *SH*-dibenzo[*b*,*d*]azepin-7(6*H*)-ones were elucidated. Improvement of the Friedel–Crafts acylation of *N*-(1,1')-biphenyl-2-yl-glycine derivatives¹⁷ was achieved by the introduction of the amino-protective groups with electronwithdrawing properties. ¹H NMR revealed that *N*-acyl *SH*dibenzo[*b*,*d*]azepin-7(6*H*)-ones exist in *E*-amide in preference to *Z*-amide in solution, which was also supported by DFT calculations. The equilibration of the amide diastereomer

means that the exocyclic bond (axis 3) is not in concert with the endocyclic axes (axis 1, axis 2). Additionally, stable atropisomers $[(a^1R, a^2R) \text{ and } (a^1S, a^2S)]$ of 4-methyl derivatives of N-acyl-5H-dibenzo[b,d]azepin-7(6H)-ones were isolated. Similarly, the atropisomers of 4-methyl derivatives of N-sulfonyl 5H-dibenzo [b,d] azepin-7(6H)-ones were isolated. The separated isomers showed a high energy barrier to rotation (ΔG^{\ddagger} = 116.0–131.6 kJ/mol), and X-ray crystal structure analysis of the racemate of 4-methyl-5-tosyl-5,6dihydro-7*H*-dibenzo [b,d] azepin-7-one showed that it possessed the stable relative configuration of (a^1R, a^2R) and $(a^{1}S, a^{2}S)$ in a unit cell. It was revealed that axial chirality caused by the $Ar-N(SO_2)$ axis moves together concertedly with the axis at the biphenyl to form the stable relative configuration of (a^1R^*, a^2R^*) . The preliminary results on the difference between the atropisomers of N-sulfonyl 5Hdibenzo[b,d]azepin-7(6H)-ones in the potency of potassium channel Kv1.3 blockade might be a clue for the design of potassium channel inhibitors. More detailed investigation through the structure-activity relationship (SAR) study of N-acyl/N-sulfonyl 5H-dibenzo[b,d]azepin-7(6H)-ones is under consideration.

EXPERIMENTAL SECTION

General Information. All reagents were purchased from commercial suppliers and used as received. Reaction mixtures were stirred magnetically, and the reactions were monitored by thin-layer chromatography (TLC) on precoated silica gel plates. For the reactions that require heating, an oil bath was used. Column chromatography was performed using silica gel (45-60 μ m). For recrystallizaton, crude products were dissolved in AcOEt/diisopropyl ether/hexane, and the precipitated crystals were collected. Extracted solutions were dried over anhydrous Na2SO4. Solvents were evaporated under reduced pressure. NMR spectra were recorded on a spectrometer at 600 MHz for ¹H NMR and at 150 MHz for ¹³C NMR at 296 K unless otherwise stated. Tetramethylsilane (TMS) (δ 0.00) or residual internal CHCl₃ (δ 7.26) was used as an internal reference for the ¹H spectroscopy measurements of samples in CDCl₃. TMS (δ 0.00) or residual internal CHCl₃ (δ 77.16) was used as an internal reference for the ¹³C spectroscopy measurements of samples in $CDCl_3$. Coupling constants (*J*) are reported in hertz (Hz). Splitting patterns are abbreviated as follows: singlet (s); doublet (d); triplet (t); quartet (q); multiplet (m); and broad (br). The highresolution mass spectra (HRMS) were recorded using an ESI/TOF, APCI/TOF, or EI-MS mass spectrometer. IR spectra were recorded on an FT-IR spectrometer equipped with ATR (Diamond). Melting points were recorded on a melting point apparatus and are uncorrected. The chemical structures of S1-S10 were shown in the Supporting Information.

 \hat{N} -([1,1]-Biphenyl]-2-yl)-N-acetylglycine (1Aa). NaOH aq (930 μ L, 9.30 mmol) was added to a stirred solution of methyl ester S2a



(1.05 g, 3.70 mmol) in MeOH (7.4 mL) at rt under an argon atmosphere. After stirring for 2 h, the mixture was treated with HCl and extracted with ethyl acetate. The extract was washed with 1 M HCl aq. and brine, dried, and concentrated. The concentrate was purified by recrystallization. Colorless crystal (800.0 mg, 80%), mp 173–174 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.55 (d, 1H, J = 8.4 Hz), 7.44–7.36 (m, 6H), 7.25–7.24 (m, 2H), 4.52 (d, 1H, J = 17.4 Hz), 3.38 (d, 1H, J = 17.4 Hz), 1.95 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 172.8, 172.2, 140.3, 139.4, 138.4, 131.5, 129.8, 129.2,

129.0, 128.5, 128.1, 51.2, 22.2; IR (ATR) 2873, 1716, 1608 cm⁻¹; HRMS (ESI-TOF) m/z calcd for C₁₆H₁₅NO₃Na 292.0944 (M+Na)⁺, found 292.0951.

N-([1,1'-Biphenyl]-2-yl)-N-(4-methylbenzoyl)glycine (1Ab). Compound **1Ab** was prepared according to a similar procedure as



described for the preparation of **1Aa** from **S2a**. Colorless crystal (900.0 mg, 62%), mp 147–149 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.37–7.34 (m, 4H), 7.31 (ddd, 2H, *J* = 7.8, 7.8, 3.0 Hz), 7.26 (ddd, 1H, *J* = 7.2, 7.2, 1.8 Hz), 7.15 (dd, 2H, *J* = 7.2, 1.2 Hz), 7.05 (d, 2H, *J* = 8.4 Hz), 6.90 (d, 2H, *J* = 8.4 Hz), 4.78 (d, 1H, *J* = 17.4 Hz), 3.76 (d, 1H, *J* = 17.4 Hz), 2.27 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 173.6, 170.7, 141.2, 140.8, 138.4, 138.3, 131.4, 131.2, 129.6, 129.3, 128.9, 128.7, 128.4, 128.3, 127.9, 53.0, 21.5; IR (ATR) 2827, 1716, 1607 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₂₂H₂₀NO₃ 346.1438 (M+H)⁺, found 346.1439.

N-([1,1'-Biphenyl]-2-yl)-N-(2,2,2-trifluoroacetyl)glycine (1Ag). The benzyl ester of S2g (141.0 mg, 0.34 mmol) was dissolved in



THF/MeOH (5.0 mL), and 10% palladium on activated carbon (14.1 mg, 10% w/w) was added at rt for 18 h under a hydrogen atmosphere. The mixture was filtered and washed with 1 M HCl aq. and brine. The filtrate was dried and concentrated under reduced pressure. The concentrate was purified by recrystallization to afford **1Ag** as colorless crystals (116.0 mg, 99%), mp 190–191 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.56 (d, 1H, *J* = 7.2 Hz), 7.49 (ddd, 1H, *J* = 7.2, 7.2, 1.2 Hz), 7.45–7.38 (m, SH), 7.27 (dd, 2H, *J* = 6.6, 1.8 Hz), 4.37 (d, 1H, *J* = 17.4 Hz), 3.42 (d, 1H, *J* = 17.4 Hz); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 171.8, 158.2 (C–F, ²*J*_{C–F} = 37.6 Hz), 139.3, 137.9, 136.9, 131.6, 130.0, 129.7, 129.1, 128.7, 128.6, 128,4, 116.3 (C–F, ¹*J*_{C–F} = 289.0 Hz), 52.1; IR (ATR) 2929, 1732, 1693 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₆H₁₂F₃NO₃Na 322.0697 (M+Na)⁺, found 322.0702.

N-([1,1'-Biphenyl]-2-yl)-*N*-(methoxycarbonyl)glycine (1Ah). Compound 1Ah was prepared according to a similar procedure as



described for the preparation of **1Aa** from **S2a**, purified by recrystallization. Colorless crystal (331.0 mg, 70%), mp 138–140 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.50 (dt, 1H, *J* = 6.6, 1.8 Hz), 7.42–7.33 (m, 7H), 7.28–7.26 (m, 1H), 4.34 (d, 1H, *J* = 18.0 Hz), 3.64 (s, 3H), 3.40 (d, 1H, *J* = 18.0 Hz); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 174.6, 156.8, 139.4, 139.0, 138.9, 130.9, 129.7, 128.8, 128.6, 128.5, 128.4, 127.8, 53.5, 51.6; IR (ATR) 3070, 1770, 1664 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₆H₁₅NO₄Na 308.0893 (M+Na)⁺, found 308.0908.

General Procedure of Intramolecular Friedel–Crafts Acylation. 5-(2,2,2-Trifluoroacetyl)-5,6-dihydro-7H-dibenzo[b,d]azepin-7-one (IAg). 1Ag (1.00 g, 3.09 mmol) was dissolved in SOCl₂ (7.00 mL, 0.5 M) at reflux for 1 h under an argon atmosphere. The mixture was concentrated under reduced pressure. The concentrate was dissolved in CH₂Cl₂ (20.0 mL) at -78 °C under an argon atmosphere, and aluminum chloride (1.98 g, 14.8 mmol) was added. After being stirred at rt for 1 h, the mixture was treated with 1 M HCI



aq. and extracted with ethyl acetate. The extract was washed with 1 M HCl aq., 1 M NaHCO3 aq., and brine, dried, and concentrated. The concentrate was purified by column chromatography (silica gel, hexane/EtOAc = 4:1) to afford IAg as colorless crystals (914.0 mg, 97%), mp 95–96 °C: ¹H NMR (600 MHz, CDCl₃) E-isomer: δ 7.79 (dd, 1H, J = 8.4, 1.8 Hz), 7.68 (ddd, 1H, J = 7.5, 7.5, 1.2 Hz), 7.60-7.58 (m, 2H), 7.53-7.49 (m, 3H), 7.43 (d, 1H, J = 7.8 Hz), 5.56 (d, 1H, J = 18.6 Hz), 4.11 (d, 1H, J = 18.6 Hz); Z-isomer: δ 7.79 (dd, 1H, J = 8.4, 1.8 Hz), 7.68 (ddd, 1H, J = 7.5, 7.5, 1.2 Hz), 7.60–7.58 (m, 2H), 7.53–7.49 (m, 3H), 7.43 (d, 1H, J = 7.8 Hz), 5.07 (d, 1H, J = 21.0, 1.8 Hz), 4.37 (d, 1H, J = 21.0, 1.8 Hz); ¹³C{1H} NMR (150 MHz, CDCl₃) *E*-isomer: δ 200.9, 156.8 (C-F, ${}^{2}J_{C-F} = 37.6$ Hz), 138.5, 136.7, 136.5, 135.4, 133.9, 130.9, 130,9 129.9, 129.8, 129.7, 129.3, 127.6, 116.1 (C–F, ${}^{1}J_{C-F}$ = 289.0 Hz), 62.3; IR (ATR) 1695, 1678 cm⁻¹; HRMS (ESI-TOF) m/z calcd for C₁₅H₉F₃N 350.0646 (M +HCOO)⁻, found 350.0652.

Methyl 7-Oxo-6,7-dihydro-5H-dibenzo[b,d]azepine-5-carboxylate (IAh). Compound IAh was prepared according to a similar



procedure as described for the preparation of **IAg** from **1Ag**. Colorless crystal (31.5 mg, 84%), mp 130–131 °C: ¹H NMR (600 MHz, CDCl₃) *E*-isomer: δ 7.81 (d, 1H, *J* = 7.8 Hz), 7.65 (dd, 1H, *J* = 7.2, 7.2 Hz), 7.59–7.52 (m, 2H), 7.50–7.43 (m, 3H), 7.34 (d, 1H, *J* = 6.6 Hz), 5.36 (d, 1H, *J* = 18.6 Hz), 4.09 (d, 1H, *J* = 18.6 Hz), 3.55 (s, 3H); *Z*-isomer: δ 7.81 (d, 1H, *J* = 7.8 Hz), 7.65 (dd, 1H, *J* = 7.2, 7.2 Hz), 7.59–7.52 (m, 2H), 7.50–7.43 (m, 3H), 7.34 (d, 1H, *J* = 6.6 Hz), 5.14 (d, 1H, *J* = 19.2 Hz), 4.10 (d, 1H, *J* = 19.2 Hz), 3.67 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) *E*-isomer: δ 203.8, 155.9, 139.0, 137.7, 137.3, 136.4, 133.4, 130.7, 129.9, 129.8, 129.6, 129.2, 128.6, 128.0, 62.6, 53.5; IR (ATR) 1699, 1686 cm⁻¹; HRMS (ESITOF) *m*/*z* calcd for C₁₆H₁₃NO₃Na 297.0788 (M+Na)⁺, found 290.0792.

N-(3-Methyl-[1,1'-biphenyl]-2-yl)-N-(2,2,2-trifluoroacetyl)glycine (**1Bg**). K₂CO₃ (265.9 mg, 1.92 mmol) was added to a stirred solution



of amide S5g (358.0 mg, 1.28 mmol) in DMF (2.6 mL) at rt under an argon atmosphere and treated with benzyl bromoacetate (181.0 μ L, 1.15 mmol) for 2 days. The reaction mixture was poured into water and extracted with ethyl acetate. The extract was washed with brine, dried, and concentrated. The concentrate was dissolved in CH₂Cl₂, and TFAA (537.6 μ L, 3.84 mmol) was added at 0 °C under an argon atmosphere for 1 h. The mixture was treated with 1 M HCl aq. and extracted with ethyl acetate. The extract was washed with 1 M HCl aq., 1 M NaHCO3 aq., and brine, dried, and concentrated. The concentrate was purified by column chromatography (silica gel, hexane/ethyl acetate = 4:1) to afford benzyl ester as a crude crystal (506.0 mg, 1.50 mmol). Benzyl ester was dissolved in THF/MeOH (7.5 mL), and 10% palladium on activated carbon (50.6 mg, 10% w/ w) was added at rt for 18 h under a hydrogen atmosphere. The mixture was filtered and washed with 1 M HCl aq. and brine. The filtrate was dried and concentrated under reduced pressure. The concentrate was purified by recrystallization to afford **1Bg** as colorless crystals (334.2 mg, 52%), mp 168–169 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.42–7.38 (m, 2H), 7.38–7.34 (m, 2H), 7.30 (d, 1H, *J* = 6.0 Hz), 7.19–7.18 (m, 3H), 4.06 (d, 1H, *J* = 17.2 Hz), 3.62 (d, 1H, *J* = 17.2 Hz), 2.46 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 171.6, 158.5 (C–F, ²*J*_{C–F} = 37.6 Hz), 141.0, 138.6, 137.2, 137.0, 130.1, 129.4, 129.3, 129.2, 128.9, 128.8, 128.4, 128.2, 116.1 (C–F, ¹*J*_{C–F} = 287.6 Hz), 53.8, 18.3; IR (ATR) 2948, 1740, 1692 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₇H₁₄F₃NO₃Na 360.0818 (M+Na)⁺, found 360.0826.

N-(Methoxycarbonyl)-N-(3-methyl-[1,1'-biphenyl]-2-yl)glycine (1Bh). Compound 1Bh was prepared according to a similar procedure



as described for the preparation of **1Aa** from **S2a**. Colorless crystal (232.5 mg, 99%), mp 179–180 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.42–7.39 (m, 2H), 7.35 (ddd, 1H, *J* = 7.2, 7.2, 1.2 Hz), 7.28 (dd, 1H, *J* = 7.8, 7.8 Hz), 7.26–7.23 (m, 1H), 7.22 (dd, 2H, *J* = 9.0, 1.8 Hz), 7.18 (dd, 1H, *J* = 6.6, 1.8 Hz), 3.88 (d, 1H, *J* = 17.7 Hz), 3.78 (s, 3H), 3.33 (d, 1H, *J* = 17.7 Hz), 2.40 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 172.9, 157.1, 139.6, 139.3, 138.0, 137.8, 130.4, 128.8, 128.7, 128.6, 128.5, 128.3, 128.0, 127.7, 53.6, 52.1, 18.2; IR (ATR) 3061, 1755, 1670 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₇H₁₇NO₄Na 322.1050 (M+Na)⁺, found 332.1051.

4-Methyl-5-(2,2,2-trifluoroacetyl)-5,6-dihydro-7H-dibenzo[b,d]azepin-7-one (IBg). Compound IBg was prepared according to a



similar procedure as described for the preparation of IAg from 1Ag. Colorless crystal (37.4 mg, 99%), mp 84-85 °C: ¹H NMR (600 MHz, CDCl₃) *E*-isomer: δ 7.73 (dd, 1H, *J* = 7.8, 1.8 Hz), 7.66 (ddd, 1H, J = 7.6, 7.6, 1.6 Hz), 7.52–7.45 (m, 3H), 7.38 (dd, 2H, J = 6.4, 6.4 Hz), 5.50 (d, 1H, J = 18.0 Hz), 3.99 (d, 1H, J = 18.0 Hz), 2.37 (s, 3H); Z-isomer: δ 7.73 (dd, 1H, J = 7.8, 1.8 Hz), 7.66 (ddd, 1H, J = 7.6, 7.6, 1.6 Hz), 7.52–7.45 (m, 3H), 7.38 (dd, 2H, J = 6.4, 6.4 Hz), 5.07 (d, 1H, J = 19.6, 1.8 Hz), 4.26 (d, 1H, J = 19.6, 1.8 Hz), 2.30 (s, 3H); $^{13}C{1H}$ NMR (150 MHz, CDCl₃) *E*-isomer: δ 201.3, 157.4 $(C-F, {}^{2}J_{C-F} = 111.2 \text{ Hz})$, 139.3, 136.9, 136.1, 135.4, 135.2, 133.7, 131.5, 130.6, 129.7, 129.5, 129.2, 128.5, 115.8 (C-F, ${}^{1}J_{C-F} = 865.5$ Hz), 61.6, 17.6; Z-isomer: δ 200.5, 155.6 (C-F, ${}^{2}J_{C-F} = 37.6$ Hz), 137.1, 137.0, 136.8, 135.1, 134.8, 134.1, 131.7, 130.1, 129.7, 129.2, 129.0, 128.9, 116.2 (C–F, ${}^{1}J_{C-F}$ = 289.0 Hz), 61.8, 17.4; IR (ATR) 1700, 1686 cm⁻¹; HRMS (ESI-TOF) m/z calcd for $C_{17}H_{11}F_{3}NO_{2}$ 318.0747 (M-H)⁻, found 318.0743. Separation of atropisomers. CHIRALPAK IA (1.0 cm $\phi \times 25$ cm): eluent, 30% 2-propanol in hexane; flow rate, 0.5 mL/min; temperature, 25 °C; detection, 254 nm; former peak, retention time = 9.4 min; $[\alpha]_D^{20}$ +12.2 as 99.5% ee (c 0.15, CHCl₃); latter peak, retention time = 13.8 min; $[\alpha]_{\text{D}}^{20} - 12.1$ as 99.9% ee (c 0.35, CHCl₃).

Methyl 4-Methyl-7-oxo-6,7-dihydro-5H-dibenzo[b,d]azepine-5carboxylate (IBh). Compound IBh was prepared according to a



similar procedure as described for the preparation of IAg from 1Ag. Colorless crystal (32.3 mg, 96%), mp 116-118 °C: ¹H NMR (600 MHz, $CDCl_3$) *E*-isomer: δ 7.77 (dd, 1H, *J* = 8.4, 1.2 Hz), 7.63 (ddd, 1H, J = 7.8, 7.8, 1.2 Hz), 7.50–7.45 (m, 2H), 7.40–7.35 (m, 2H), 7.34-7.31 (m, 1H), 5.31 (d, 1H, J = 18.6 Hz), 3.98 (d, 1H, J = 18.6 Hz), 3.52 (s, 3H), 2.30 (s, 3H); Z-isomer: δ 7.77 (dd, 1H, J = 8.4, 1.2 Hz), 7.63 (ddd, 1H, J = 7.8, 7.8, 1.2 Hz), 7.50-7.45 (m, 2H), 7.39-7.35 (m, 2H), 7.34-7.30 (m, 1H), 5.08 (d, 1H, J = 18.6 Hz), 4.00 (d, 1H, J = 18.6 Hz), 3.63 (s, 3H), 2.34 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) E-isomer: δ 204.2, 155.8, 138.4, 137.7, 136.4, 136.0, 134.7, 133.2, 131.1, 129.7, 129.6, 129.1, 128.6, 128.5, 61.7, 53.5, 17.7; IR (ATR) 1705, 1678 cm⁻¹; HRMS (ESI-TOF) m/z calcd for C17H15NO3SK 320.0684 (M+K)+, found 320.0685. Separation of atropisomers. CHIRALPAK IA (1.0 cm $\phi \times 25$ cm): eluent, 30% 2propanol in hexane; flow rate, 0.5 mL/min; temperature, 25 °C; detection, 254 nm; former peak, retention time = 10.3 min; $[\alpha]_D^{20}$ +145.8 as 94.7% ee (c 0.07, CHCl₃); latter peak, retention time = 15.0 min; $[\alpha]_{D}^{20}$ –146.8 as 94.8% ee (c 0.06, CHCl₃).

N-([1,1'-Biphenyl]-2-yl)-*N*-tosylglycine (1Ac). NaOH aq. (200.0 μ L, 0.50 mmol) was added to a stirred solution of methyl ester S10c



(116.0 mg, 0.29 mmol) in MeOH (4.0 mL) at rt under an argon atmosphere. After stirring for 2 h, the mixture was treated with HCl and extracted with ethyl acetate. The extract was washed with 1 M HCl aq. and brine, dried, and concentrated. The concentrate was purified by recrystallization to afford **1Ac** as colorless crystals (159.7 mg, 84%), mp 193–194 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.62 (d, 2H, *J* = 8.4 Hz), 7.38–7.35 (m, 5H), 7.32–7.26 (m, 6H), 3.99 (br, 2H), 2.44 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 173.2, 144.0, 141.4, 138.7, 137.4, 137.1, 131.8, 130.7, 129.6, 129.1, 128.9, 128.5, 128.2, 127.9, 52.0, 21.7; IR (ATR) 3200, 1743, 1327, 1140 cm⁻¹; HRMS (ESI-TOF) *m/z* calcd for C₂₁H₁₉NO₄SNa 404.0927 (M +Na)⁺, found 404.0936.

N-([1,1'-Biphenyl]-2-yl)-N-(methylsulfonyl)glycine (1Ad). Compound 1Ad was prepared according to a similar procedure as



described for the preparation of **1Ac** from **S10c**. Colorless crystal (186.0 mg, 70%), mp 100–101 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.63–7.62 (m, 1H), 7.51 (dd, 2H, *J* = 7.2, 1.8 Hz), 7.46–7.39 (m, 6H), 4.01 (br, 2H), 3.15 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 174.1, 141.6, 138.6, 137.4, 132.1, 129.9, 129.3, 129.2, 128.7, 128.1, 52.1, 42.6; IR (ATR) 3365, 1706, 1323, 1142 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₅H₁₅NO₄SNa 328.0614 (M+Na)⁺, found 328.0622.

N-([1,1'-Biphenyl]-2-yl)-N-(2-nitrobenzenesulfonyl)glycine (1Ae). Compound 1Ae was prepared according to a similar procedure as



described for the preparation of **1Ac** from **S10c**. Colorless crystal (163.0 mg, 66%), mp 120–121 °C: ¹H NMR (600 MHz, CDCl₃) δ 8.27 (dd, 1H, *J* = 8.4, 8.4 Hz), 7.87 (d, 1H, *J* = 7.8 Hz), 7.76–7.73

(m, 1H), 7.69 (dd, 1H, *J* = 7.2, 7.2, 1.8 Hz), 7.64 (dd, 1H, *J* = 7.2, 7.2 Hz), 7.56 (d, 1H, *J* = 7.8 Hz), 7.43 (dd, 1H, *J* = 8.4, 8.4 Hz), 7.39 (dd, 1H, *J* = 8.4, 8.4, 1.8 Hz), 7.31–7.27 (m, 3H), 7.14–7.15 (m, 2H), 3.60 (br, 2H); $^{13}C\{1H\}$ NMR (150 MHz, CDCl₃) δ 172.6, 148.0, 141.9, 138.3, 136.8, 135.2, 134.1, 133.8, 131.9, 131.8, 131.7, 129.5, 128.8, 128.6, 128.4, 127.8, 126.1, 125.4, 124.6, 53.0; IR (ATR) 3276, 1758, 1539, 1349, 1334, 1121 cm⁻¹; HRMS (ESI-TOF) *m/z* calcd for C₂₀H₁₆N₂O₆SNa 435.0621 (M+Na)⁺, found 435.0625.

N-([1,1'-Biphenyl]-2-yl)-N-(4-nitrobenzenesulfonyl)glycine (1Af). Compound 1Af was prepared according to a similar procedure as



described for the preparation of **1Ac** from **S10c**. Colorless crystal (249.6 mg, 85%), mp 179–181 °C: ¹H NMR (600 MHz, CDCl₃) δ 8.25 (ddd, 2H, *J* = 8.4, 2.4, 2.4 Hz), 7.87 (dd, 2H, *J* = 8.4, 2.4 Hz), 7.44 (ddd, 1H, *J* = 6.6, 6.6, 2.4 Hz), 7.40–7.32 (m, 6H), 7.31–7.29 (m, 2H), 4.42 (br, 2H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 173.0, 150.2, 146.1, 141.7, 138.3, 136.4, 132.2, 130.6, 129.7, 129.4, 128.9, 128.7, 128.6, 128.1, 124.1, 52.7; IR (ATR) 3318, 1774, 1528, 1338, 1307, 1138 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₂₀H₁₆N₂O₆SNa 435.0621 (M+Na)⁺, found 435.0626.

5-Tosyl-5,6-dihydro-7H-dibenzo[b,d]azepin-7-one (IIAc). Compound IIAc was prepared according to a similar procedure as



described for the preparation of IAg from 1Ag. Colorless crystal (33.0 mg, 91%), mp 124–125 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.64–7.61 (m, 1H), 7.52 (dd, 1H, *J* = 8.4, 1.6 Hz), 7.49–7.45 (m, 2H), 7.42–7.39 (m, 2H), 7.27 (ddd, 1H, *J* = 7.8, 7.8, 1.2 Hz), 7.17 (d, 2H, *J* = 7.8 Hz), 7.04 (d, 1H, *J* = 6.6 Hz), 6.84 (d, 2H, *J* = 7.8 Hz), 5.27 (d, 1H, *J* = 19.2 Hz), 4.38 (d, 1H, *J* = 19.2 Hz), 2.26 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 203.0, 143.1, 139.2, 137.5, 137.1, 137.0, 136.2, 133.0, 130.9, 130.8, 130.2, 130.0, 129.9, 129.5, 129.4, 127.9, 126.8, 63.7, 21.5; IR (ATR) 1675, 1335, 1155 cm⁻¹; HRMS (ESI-TOF) *m/z* calcd for C₂₁H₁₇NO₃SNa 386.0821 (M +Na)⁺, found 386.0822.

5-(Methylsulfonyl)-5,6-dihydro-7H-dibenzo[b,d]azepin-7-one (IIAd). Compound IIAd was prepared according to a similar



procedure as described for the preparation of **IAg** from **1Ag**. Colorless crystal (32.0 mg, 86%), mp 170–171 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.83 (d, 1H, *J* = 7.2 Hz), 7.71 (ddd, 1H, *J* = 7.6, 7.6, 1.2 Hz), 7.61–7.57 (m, 2H), 7.56–7.53 (m, 3H), 7.51–7.48 (m, 1H), 5.19 (d, 1H, *J* = 19.8 Hz), 4.36 (d, 1H, *J* = 19.8 Hz), 2.41 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 203.3, 139.1, 137.6, 136.8, 136.5, 133.9, 130.9, 130.6, 130.4, 130.3, 130.2, 129.8, 129.0, 64.0, 40.5; IR (ATR) 1686, 1337, 1153 cm⁻¹; HRMS (ESI-TOF) *m/z* calcd for C₁₅H₁₃NO₃SK 326.0248 (M+K)⁺, found 326.0252.

5-[(2-Nitrophenyl)sulfonyl]-5,6-dihydro-7H-dibenzo[b,d]vazepin-7-one (IIAe). Compound IIAe was prepared according to a similar procedure as described for the preparation of IAg from 1Ag.



Colorless crystal (28.6 mg, 74%), mp 194–195 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.62–7.58 (m, 2H), 7.54 (ddd, 1H, *J* = 7.8, 7.8, 1.8 Hz), 7.50 (ddd, 1H, *J* = 7.6, 7.6, 1.2 Hz), 7.44–7.39 (m, 3H), 7.32 (dd, 1H, *J* = 7.8, 7.8 Hz), 7.28–7.25 (m, 2H), 7.18 (dd, 1H, *J* = 7.2, 7.2 Hz), 7.01 (d, 1H, *J* = 7.2 Hz), 5.43 (d, 1H, *J* = 19.6 Hz), 4.46 (d, 1H, *J* = 19.6 Hz); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 202.6, 146.9, 139.5, 137.0, 136.5, 135.9, 133.5, 133.0, 132.9, 131.6, 131.2, 131.0, 130.8, 130.7, 130.1, 128.9, 128.3, 128.2, 124.1, 64.7; IR (ATR) 1688, 1541, 1362, 1297, 1166 cm⁻¹; HRMS (ESI-TOF) *m/z* calcd for C₂₀H₁₄N₂O₅SNa 417.0516 (M+Na)⁺, found 417.0522.

5-[(4-Nitrophenyl)sulfonyl]-5,6-dihydro-7H-dibenzo[b,d]azepin-7-one (IIAf). Compound IIAf was prepared according to a similar



procedure as described for the preparation of **IAg** from **1Ag**. Colorless crystal (386.4 mg, 69%), mp 168–169 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.84 (ddd, 2H, *J* = 9.0, 2.4, 2.4 Hz), 7.71–7.69 (m, 1H), 7.55–7.51 (m, 3H), 7.43–7.40 (m, 3H), 7.34 (ddd, 1H, *J* = 7.2, 7.2, 1.8 Hz), 7.27 (ddd, 1H, *J* = 7.2, 7.2, 1.8 Hz), 6.96 (d, 1H, *J* = 7.2 Hz), 5.33 (d, 1H, *J* = 19.2 Hz), 4.45 (d, 1H, *J* = 19.2 Hz); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 201.5, 149.8, 145.2, 138.8, 137.1, 136.0, 135.9, 133.4, 131.1, 131.0, 130.7, 130.4, 130.2, 129.6, 128.5, 127.9, 123.8, 64.0; IR (ATR) 1686, 1523, 1357, 1348, 1171 cm⁻¹; HRMS (APCITOF) *m*/*z* calcd for C₂₂H₂₀NO₄S 394.0551 (M–H)⁻, found 393.0552.

N-(3-Methyl-[1,1'-biphenyl]-2-yl)-N-tosylglycine (1Bc). Compound 1Bc was prepared according to a similar procedure as



described for the preparation of **1Ac** from **S10c**. Colorless crystal (195.0 mg, 93%), mp 208–210 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.56 (d, 2H, *J* = 8.4 Hz), 7.33–7.30 (m, 1H), 7.29–7.26 (m, 3H), 7.25–7.22 (m, 5H), 7.09 (dd, 1H, *J* = 7.8, 2.4 Hz), 4.11 (d, 1H, *J* = 17.6 Hz), 3.97 (d, 1H, *J* = 17.6 Hz), 2.44 (s, 3H), 2.23 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 171.1, 144.2, 143.4, 139.7, 139.5, 137.0, 136.5, 131.3, 130.0, 129.7, 129.6, 128.6, 128.3, 128.0, 127.6, 53.4, 21.7, 20.0; IR (ATR) 3201, 1730, 1337, 1151 cm⁻¹; HRMS (ESI-TOF) *m/z* calcd for C₂₂H₂₁NO₄SNa 418.1084 (M +Na)⁺, found 418.1086.

N-(3-Methyl-[1,1'-biphenyl]-2-yl)-N-(methylsulfonyl)glycine (1Bd). Compound 1Bd was prepared according to a similar procedure



as described for the preparation of **1Ac** from **S10c**. Colorless crystal (192.9 mg, 86%), mp 162–165 °C: ¹H NMR (600 MHz, CDCl₃) δ

7.41–7.36 (m, 5H), 7.31–7.29 (m, 2H), 7.17–7.14 (m, 1H), 4.42 (d, 1H, J = 18.0 Hz), 4.03 (d, 1H, J = 18.0 Hz), 2.75 (s, 3H), 2.54 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 173.5, 142.7, 139.9, 139.3, 138.4, 131.4, 129.8, 129.7, 128.7, 128.2, 127.9, 53.3, 42.2, 19.9; IR (ATR) 3020, 1758, 1327, 1138 cm⁻¹; HRMS (ESI-TOF) m/z calcd for C₁₆H₁₇NO₄SNa 342.0771 (M+Na)⁺, found 342.0774.

N-(3-Methyl-[1,1'-biphenyl]-2-yl)-N-([2-nitrophenyl]sulfonyl)glycine (1Be). Compound 1Be was prepared according to a similar



procedure as described for the preparation of **1Ac** from **S10c**. Colorless crystal (150.5 mg, 68%), mp 199–201 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.70 (d, 1H, *J* = 7.8 Hz), 7.66 (dd, 1H, *J* = 7.8, 7.8 Hz), 7.55–7.52 (m, 2H), 7.32–7.28 (m, 3H), 7.23 (dd, 2H, *J* = 7.8, 7.8 Hz), 7.16 (d, 2H, *J* = 7.8 Hz), 7.06 (d, 1H, *J* = 7.2 Hz), 4.52 (d, 1H, *J* = 18.0 Hz), 4.16 (d, 1H, *J* = 18.0 Hz), 2.41 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 171.1, 148.5, 143.5, 140.1, 139.6, 136.4, 133.9, 133.7, 132.0, 131.7, 131.6, 130.3, 129.5, 129.0, 128.1, 127.7, 124.3, 54.2, 20.3; IR (ATR) 3028, 1708, 1543, 1366, 1364, 1166 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₂₁H₁₈N₂O₆SNa 449.0778 (M+Na)⁺, found 449.0781.

N-(3-Methyl-[1,1'-biphenyl]-2-yl)-N-([4-nitrophenyl]sulfonyl)glycine (1Bf). Compound 1Bf was prepared according to a similar



procedure as described for the preparation of **1Ac** from **S10c**. Colorless crystal (235.4 mg, 77%), mp 185–187 °C: ¹H NMR (600 MHz, CDCl₃) δ 8.14 (ddd, 2H, *J* = 9.0, 2.4, 2.4 Hz), 7.78 (ddd, 2H, *J* = 9.0, 2.4, 2.4 Hz), 7.78 (ddd, 2H, *J* = 9.0, 2.4, 2.4 Hz), 7.78 (ddd, 2H, *J* = 9.0, 2.4, 2.4 Hz), 7.78 (ddd, 2H, *J* = 7.8, 7.28 (m, 3H), 7.22 (dd, 2H, *J* = 7.8, 7.8 Hz), 7.19 (dd, 2H, *J* = 7.8, 1.2 Hz), 7.09 (dd, 1H, *J* = 6.6, 1.8 Hz), 4.29 (d, 2H, *J* = 1.8 Hz), 2.37 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 171.7, 150.1, 145.6, 143.1, 139.8, 139.4, 136.7, 131.6, 130.3, 129.5, 129.2, 128.0, 127.7, 123.8, 53.9, 20.1; IR (ATR) 3318, 1775, 1528, 1339, 1307, 1138 cm⁻¹; HRMS (ESI-TOF) *m/z* calcd for C₂₁H₁₇N₂O₆S 425.0813 (M–H)⁻, found 425.0812.

4-Methyl-5-tosyl-5,6-dihydro-7H-dibenzo[b,d]azepin-7-one (**IIBc**). Compound **IIBc** was prepared according to a similar procedure



as described for the preparation of **IAg** from **1Ag**. Colorless crystal (25.3 mg, 99%), mp 159–160 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.42–7.36 (m, 3H), 7.27 (d, 1H, *J* = 1.8 Hz), 7.23–7.16 (m, 5H), 6.83 (d, 2H, *J* = 7.8 Hz), 5.12 (d, 1H, *J* = 19.6 Hz), 4.31 (d, 1H, *J* = 19.6 Hz), 2.57 (s, 3H), 2.28 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 203.3, 142.9, 140.1, 140.0, 138.3, 137.5, 136.4, 136.2, 133.0, 131.9, 130.0, 129.8, 129.5, 129.3, 129.0, 127.8, 126.9, 63.0, 21.5, 19.3; IR (ATR) 1682, 1344, 1161 cm⁻¹; HRMS (ESI-TOF) *m/z* calcd for C₂₂H₁₉NO₃SNa 400.0978 (M+Na)⁺, found 400.0980. Separation of atropisomers. CHIRALPAK IB (1.0 cm $\phi \times 25$ cm): eluent, 30% 2-propanol in hexane; flow rate, 0.3 mL/min; temperature, 25 °C; detection, 254 nm; former peak, retention time = 24.1 min; $[\alpha]_D^{20}$

-65.8 as 96.8% ee (*c* 0.23, CHCl₃); latter peak, retention time = 28.5 min; $[\alpha]_{\rm D}^{20}$ +64.9 as 96.1% ee (*c* 0.21, CHCl₃).

4-Methyl-5-(methylsulfonyl)-5,6-dihydro-7H-dibenzo[b,d]azepin-7-one (**IIBd**). Compound **IIBd** was prepared according to a



similar procedure as described for the preparation of **IAg** from **1Ag**. Colorless crystal (28.0 mg, 72%), mp 177–178 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.76 (dd, 1H, *J* = 8.4, 1.6 Hz), 7.70 (ddd, 1H, *J* = 7.8, 7.8, 1.2 Hz), 7.59 (dd, 1H, *J* = 7.8, 1.2 Hz), 7.52 (dd, 1H, *J* = 7.6, 7.6 Hz), 7.42 (dd, 1H, *J* = 7.8, 7.8 Hz), 7.39–7.35 (m, 2H), 5.08 (d, 1H, *J* = 20.0 Hz), 4.32 (d, 1H, *J* = 20.0 Hz), 2.52 (s, 3H), 2.28 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 203.6, 139.9, 139.8, 138.4, 136.9, 135.6, 133.9, 132.2, 130.2, 130.1, 129.5, 129.0, 128.8, 63.6, 40.5, 19.1; IR (ATR) 1683, 1337, 1151 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₆H₁₅NO₃SNa 324.0665 (M+Na)⁺, found 324.0665. Separation of atropisomers. CHIRALPAK IA (1.0 cm $\phi \times 25$ cm): eluent, 30% 2-propanol in hexane; flow rate, 0.5 mL/min; temperature, 25 °C; detection, 254 nm; former peak, retention time = 30.0 min; $[\alpha]_D^{20}$ +89.8 as 97.0% ee (*c* 0.23, CHCl₃),; latter peak, retention time = 34.9 min; $[\alpha]_D^{20}$ –90.8 as 98.7% ee (*c* 0.27, CHCl₃).

4-Methyl-5-([2-nitrophenyl]sulfonyl)-5,6-dihydro-7H-dibenzo-[b,d]azepin-7-one (IIBe). Compound IIBe was prepared according to



a similar procedure as described for the preparation of **IAg** from **1Ag**. Colorless crystal (61.0 mg, 83%), mp 185–187 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.49 (dd, 1H, *J* = 7.2, 1.2 Hz), 7.45–7.39 (m, 4H), 7.32 (ddd, 1H, *J* = 7.8, 7.8, 1.2 Hz), 7.27 (dd, 1H, *J* = 8.4, 1.8 Hz), 7.24–7.21 (m, 2H), 7.12–7.09 (m, 2H), 5.40 (d, 1H, *J* = 19.8 Hz), 4.36 (d, 1H, *J* = 19.8 Hz), 2.51 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 202.8, 147.0, 140.2, 139.9, 137.3, 137.1, 135.0, 133.6, 133.4, 132.8, 132.2, 131.7, 131.2, 130.4, 129.7, 129.2, 128.9, 128.1, 124.1, 64.1, 19.0; IR (ATR) 1688, 1533, 1356, 1356, 1166 cm⁻¹; HRMS (ESI-TOF) *m/z* calcd for C₂₁H₁₇N₂O₅S 409.0853 (M+H)⁺, found 409.0856. Separation of atropisomers. CHIRALPAK IA (1.0 cm ϕ × 25 cm): eluent, 30% 2-propanol in hexane; flow rate, 0.5 mL/min; temperature, 25 °C; detection, 254 nm; former peak, retention time = 19.1 min; $[\alpha]_D^{20}$ +61.5 as 99.8% ee (*c* 0.55, CHCl₃); latter peak, retention time = 26.2 mi; $[\alpha]_D^{20}$ -61.1 as 99.8% ee (*c* 0.90, CHCl₃). *4-Methyl-5-([4-nitrophenyl]sulfonyl)-5,6-dihydro-7H-dibenzo*

[b,d]azepin-7-one (IIBf). Compound IIBf was prepared according to



a similar procedure as described for the preparation of **IAg** from **1Ag**. Colorless crystal (77.2 mg, 83%), mp 184–186 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.85 (ddd, 2H, *J* = 8.4, 2.4, 2.4 Hz), 7.47 (ddd, 2H, *J* = 9.0, 2.4, 2.4 Hz), 7.42 (d, 2H, *J* = 4.8 Hz), 7.36 (ddd, 1H, *J* = 7.6, 7.6, 1.2 Hz), 7.31 (dd, 1H, *J* = 7.8, 1.2 Hz), 7.22 (dd, 1H, *J* = 4.6, 4.6 Hz), 7.17 (ddd, 1H, *J* = 19.8 Hz), 4.38 (d, 1H, *J* = 19.8 Hz), 2.61 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 201.8, 149.7, 145.6, 140.1. 139.5, 138.0, 136.1, 135.2, 133.4, 132.4, 130.4, 130.1, 129.4, 129.1, 128.4, 128.1, 124.0, 63.3, 19.2; IR (ATR) 1683, 1523, 1351, 1351, 1166 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₂₁H₁₇N₂O₅S 409.0853 (M+H)⁺, found 409.0853. Separation of atropisomers. CHIRALPAK IA (1.0 cm $\phi \times 25$ cm): eluent, 30% 2-propanol in hexane; flow rate, 0.5 mL/min; temperature, 25 °C; detection, 254 nm; former peak, retention time = 22.5 min; $[\alpha]_{\rm D}^{20}$ +27.2 as 98.5% ee (*c* 0.34, CHCl₃); latter peak, retention time = 30.1 min; $[\alpha]_{\rm D}$ -27.9 as 99.8% ee (*c* 0.07, CHCl₃).

5,6-Dihydro-7H-dibenzo[b,d]azepin-7-one (2). K_2CO_3 (45.2 mg, 0.32 mmol) was added to a stirred solution of IAg (50.0 mg, 0.16



mmol) in MeOH/H₂O = 5:1 (1.6 mL) at reflux under an argon atmosphere. After being stirred at reflux for 30 min, the mixture was treated with 1 M NaHCO₃ aq. and brine, dried, and concentrated. The concentrate was purified by column chromatography (silica gel, hexane/ethyl acetate = 4:1) to afford **2** as yellow oil (33.0 mg, 99%): ¹H NMR (600 MHz, CDCl₃) δ 7.94 (dd, 1H, *J* = 7.8, 1.2 Hz), 7.63 (ddd, 1H, *J* = 7.8, 7.8, 1.2 Hz), 7.59 (dd, 1H, *J* = 7.2, 7.2, 1.2 Hz), 7.50 (dd, 1H, *J* = 7.2, 7.2, 1.2 Hz), 7.44 (ddd, 1H, *J* = 7.2, 7.2, 1.2 Hz), 7.02 (dd, 1H, *J* = 7.8, 1.2 Hz), 4.16 (s, 2H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 204.3, 147.5, 138.8, 136.9, 133.0, 132.6, 130.8, 130.5, 129.6, 129.5, 127.7, 124.6, 121.1, 63.8; IR (ATR) 3335, 1665 cm⁻¹; HRMS (ESI-TOF) *m*/*z*: calcd for C₁₄H₁₂NO 210.0913 (M+H)⁺, found 210.0914.

5-Acetyl-5,6-dihydro-7H-dibenzo[b,d]azepin-7-one (IAa). Acetyl chloride (30.7 μ L, 0.43 mmol) and pyridine (47.7 μ L, 0.58 mmol)



were added to a stirred solution of 2 (60.5 mg, 0.29 mmol) in THF (3 mL) at 0 °C under an argon atmosphere. The mixture was stirred at rt for 1.5 h, poured into aqueous HCl, and extracted with ethyl acetate. The organic phase was washed with 1 M HCl aq., 1 M NaHCO₃ aq., and brine, then dried, and concentrated. The residue was purified by column chromatography (silica gel, hexane/EtOAc = 1:2) to afford IAa as colorless crystals (24.0 mg, 33%), mp 126–127 °C: ¹H NMR (600 MHz, CDCl₃); *E*-isomer: δ 7.77 (d, 1H, *J* = 6.6 Hz), 7.65 (ddd, 1H, J = 7.2, 7.2, 1.2 Hz), 7.60 (dd, 1H, J = 7.2, 1.2 Hz), 7.53 (ddd, 1H, J = 8.4, 8.4, 1.8 Hz), 7.50–7.47 (m, 3H), 7.36 (dd, 1H, J = 7.8, 1.8 Hz), 5.71 (d, 1H, J = 18.6 Hz), 3.95 (d, 1H, J = 18.6 Hz), 1.79 (s, 3H); Z-isomer: δ 7.77 (d, 1H, J = 6.6 Hz), 7.65 (ddd, 1H, J = 7.2, 7.2, 1.2 Hz), 7.60 (dd, 1H, J = 7.2, 1.2 Hz), 7.53 (ddd, 1H, J = 8.4, 8.4, 1.8 Hz), 7.50–7.47 (m, 3H), 7.36 (dd, 1H, J = 7.8, 1.8 Hz), 4.88 (d, 1H, J = 19.6 Hz), 4.34 (d, 1H, I = 19.6 Hz), 1.79 (s, 3H); ¹³C{1H} NMR $(150 \text{ MHz}, \text{CDCl}_3) \delta 203.5, 170.2, 140.1, 138.2, 136.5, 136.4, 133.2,$ 130.8, 129.9, 129.8, 129.7, 129.2, 128.9, 127.6, 60.7, 21.9; IR (ATR) 1667, 1596 cm⁻¹; HRMS (ESI-TOF) m/z calcd for $C_{16}H_{14}NO_2$ 252.1019 (M+H)⁺, found 252.1020.

Preparation of Starting Materials (1Aa-h, 1Bc-h). N-Acyl-/ sulfonyl-(1,1')-biphenyl-2-yl-glycines **1Aa-j**, **1Be-j** were prepared in accordance with the method reported in a previous paper.⁴ The characterization of the intermediates **S1a**, **S1b**, **S1g**, **S1h**, **S2a**, **S2b**, **S2g**, **S2h**, **S3**, **S4**, **S5g**, **S5h**, **S6h**, **S7c**, **S7d**, **S7e**, **S7f**, **S8c**, **S8d**, **S8e**, **S8f**, **S9c**, **S9d**, **S9e**, **S9f**, **S10c**, **S10d**, **S10e**, and **S10f** are described in the Experimental Section. The reaction schemes are described in the Supporting Information.

N-([1,1⁻-Biphenyl]-2-yl)acetamide (**S1a**). Acetyl chloride (2.33 mL, 33 mmol) and pyridine (3.67 mL, 45 mmol) were added to a



stirred solution of 2-aminobiphenyl (5.02 g, 30 mmol) in THF (30 mL) at 0 °C under an argon atmosphere. After stirring at rt for 30 min, the mixture was treated with 1 M HCl aq. and extracted with ethyl acetate. The extract was washed with 1 M HCl aq., 1 M NaHCO₃ aq., and brine, dried, and concentrated. The concentrate was purified by column chromatography (silica gel, hexane/ethyl acetate = 1:1) to afford **S1a** as colorless crystals (5.47 g, 87%), mp 108–110 °C: ¹H NMR (600 MHz, CDCl₃) δ 8.26 (d, 1H, *J* = 8.4 Hz), 7.49 (dd, 1H, *J* = 7.6, 7.6 Hz), 7.42 (dd, 1H, *J* = 7.2, 7.2 Hz), 7.38–7.36 (m, 3H), 7.24 (d, 1H, *J* = 7.8 Hz), 7.18 (dd, 1H *J* = 7.6, 7.6 Hz), 7.13 (br, 1H), 2.02 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 168.4, 138.3, 134.8, 132.3, 130.2, 129.4, 129.2, 128.6, 128.1, 124.5, 121.8, 24.7; IR (ATR) 3287, 1659 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₄H₁₄NO 212.1070 (M+H)⁺, found 212.1074.

N-([1,1'-Biphenyl]-2-yl)-4-methylbenzamide (S1b). Compound S1b was prepared according to a similar procedure as described for



the preparation of **S1a** from 2-aminobiphenyl. Colorless crystal (6.81 g, 96%), mp 95–96 °C: ¹H NMR (600 MHz, CDCl₃) δ 8.55 (d, 1H, *J* = 8.4 Hz), 7.97 (br, 1H), 7.52–7.48 (m, 4H), 7.45–7.42 (m, 4H), 7.30 (dd, 1H, *J* = 7.8, 1.2 Hz), 7.21 (ddd, 1H, *J* = 7.2, 7.2, 1.2 Hz), 7.19 (d, 2H, *J* = 7.8 Hz), 2.37 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 165.1, 142.4, 138.3, 135.2, 132.3, 132.1, 130.1, 129.5, 129.4, 128.8, 128.3, 127.0, 124.3, 121.2, 21.6; IR (ATR) 3311, 1709 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₂₀H₁₈NO 288.1383 (M+H)⁺, found 288.1391.

N-([1,1'-Biphenyl]-2-yl)-2,2,2-trifluoroacetamide (**S1g**). TFAA (168.0 μ L, 1.20 mmol) was added to a solution of 2-aminobiphenyl



(169.0 mg, 1.00 mmol) in CH₂Cl₂ (5.00 mL) at 0 °C. After stirring at rt for 20 min, the mixture was treated with 1 M HCl aq. and extracted with ethyl acetate. The extract was washed with 1 M HCl aq., 1 M NaHCO₃ aq., and brine, dried, and concentrated. The concentrate was purified by recrystallization to afford **S1g** as colorless crystals (263.0 mg, 99%), mp 88–89 °C: ¹H NMR (600 MHz, CDCl₃) δ 8.29 (d, 1H, *J* = 8.4 Hz), 7.99 (br, 1H), 7.53–7.51 (m, 2H), 7.47–7.43 (m, 2H), 7.37–7.29 (m, 4H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 154.7 (C–F, ²*J*_{C–F} = 37.6 Hz), 136.9, 133.3, 132.3, 130.5, 129.6, 129.2, 128.9, 128.8, 126.4, 121.5, 115.8 (C–F, ¹*J*_{C–F} = 289.0 Hz); IR (ATR) 3244, 1709 cm⁻¹; HRMS (ESI-TOF) *m/z* calcd for C₁₄H₉F₃NO 264.0642 (M–H)⁻, found 264.0639.

Methyl [1,1'-Biphenyl]-2-ylcarbamate (S1h). Compound S1h was prepared according to a similar procedure as described for the



preparation of **S1a** from 2-aminobiphenyl. Colorless crystal (421.3 mg, 93%), mp 56–57 °C: ¹H NMR (600 MHz, CDCl₃) δ 8.14 (br, 1H), 7.48 (dd, 2H, *J* = 7.8, 7.8 Hz), 7.42–7.34 (m, 4H), 7.22 (dd,

1H, *J* = 7.2, 1.2 Hz), 7.13 (ddd, 1H, *J* = 7.4, 7.4, 1.2 Hz), 3.71 (s, 3H), 6.66 (br, 1H); $^{13}C{1H}$ NMR (150 MHz, CDCl₃) δ 154.1, 138.2, 134.9, 131.5, 130.3, 129.4, 129.3, 128.6, 128.1, 123.5, 119.7, 52.4; IR (ATR) 3412, 1729 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₄H₁₄NO₂ 228.1019 (M+H)⁺, found 228.1010.

Methyl N-([1,1'-Biphenyl]-2-yl)-N-acetylglycinate (S2a). Sodium hydride (60% oil) (1.5 mg, 37.5 mmol) was added to a stirred



solution of S1a (5.30 g, 25.0 mmol) in DMF (50.0 mL) at 0 °C under an argon atmosphere. After stirring at rt for 20 min, the mixture was cooled to 0 °C and treated with methyl bromoacetate (3.46 mL, 37.5 mmol). After being stirred at rt for 1 h, the mixture was treated with 1 M HCl aq. and extracted with ethyl acetate. The extract was washed with 1 M HCl aq., 1 M NaHCO3 aq., and brine, dried, and concentrated. The concentrate was purified by column chromatography (silica gel, hexane/EtOAc = 1:2) to afford S2a as colorless crystals (7.76 g, 99%), mp 112-114 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.59 (dd, 1H, J = 7.8, 1.8 Hz), 7.44–7.39 (m, 5H), 7.38– 7.35 (m, 1H), 7.27–7.25 (m, 2H), 4.54 (d, 1H, J = 17.4 Hz), 3.68 (s, 3H), 3.30 (d, 1H, J = 17.4 Hz), 1.96 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 171.3, 169.7, 140.5, 139.5, 138.5, 131.4, 130.1, 129.0, 128.9, 128.6, 128.0, 52.2, 50.7, 22.3; IR (ATR) 1749, 1658 cm⁻¹; HRMS (ESI-TOF) m/z calcd for C₁₇H₁₇NO₃Na 306.1101 (M+Na)⁺, found 306.1107.

Methyl N-([1,1'-Biphenyl]-2-yl)-N-(4-methylbenzoyl)glycinate (**S2b**). Compound **S2b** was prepared according to a similar procedure



as described for the preparation of **S2a** from **S1a**. Colorless crystal (3.03 g, 82%), mp 99–100 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.39–7.34 (m, 4H), 7.31 (d, 2H, *J* = 4.2 Hz), 7.25–7.23 (m, 1H), 7.21 (dd, 2H, *J* = 7.8, 1.2 Hz), 7.09 (d, 2H, *J* = 8.4 Hz), 6.91 (d, 2H, *J* = 7.8 Hz), 4.78 (d, 1H, *J* = 17.4 Hz), 3.74 (s, 3H), 3.65 (d, 1H, *J* = 17.4 Hz), 2.27 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 170.2, 169.9, 141.5, 140.5, 138.5, 138.1, 131.6, 131.3, 129.9, 129.2, 128.9, 128.7, 128.5, 128.3, 128.1, 127.8, 52.5, 52.3, 21.5; IR (ATR) 1604, 1607 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₂₃H₂₂NO₃ 360.1594 (M +H)⁺, found 360.1594.

Benzyl N-([1,1'-Biphenyl]-2-yl)-N-(2,2,2-trifluoroacetyl)glycinate (**S2g**). K₂CO₃ (124.4 mg, 0.90 mmol) was added to a stirred solution



of **S1g** (159.0 mg, 0.60 mmol) in DMF (1.0 mL) at rt under an argon atmosphere and treated with benzyl bromoacetate (75.0 μ L, 0.8 mmol) for 2 days. The reaction mixture was poured into water and extracted with ethyl acetate. The extract was washed with brine, dried, and concentrated. The concentrate was dissolved in CH₂Cl₂, and TFAA (252.0 μ L, 1.80 mmol) was added at 0 °C under an argon atmosphere for 1 h. The mixture was treated with 1 M HCl aq. and extracted with ethyl acetate. The extract was washed with 1 M HCl aq. 1 M NaHCO₃ aq., and brine, dried, and concentrated. The concentrate was purified by column chromatography (silica gel, hexane/ethyl acetate = 4:1) to afford **S2g** as colorless crystals (149.0 mg, 82%), mp 82–83 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.54 (d, 1H, J = 8.4 Hz), 7.48 (ddd, 1H, J = 7.6, 7.6, 1.2 Hz), 7.43–7.33 (m,

8H), 7.29–7.27 (m, 4H), 5.14 (d, 1H, J = 12.4 Hz), 5.09 (d, 1H, J = 12.4 Hz), 4.41 (d, 1H, J = 17.1 Hz), 3.41 (d, 1H, J = 17.1 Hz); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 167.2, 158.1 (C-F, ² $J_{C-F} = 36.1$ Hz), 139.3, 137.9, 137.1, 135.0, 131.5, 129.9 (C-F, ⁵ $J_{C-F} = 5.8$ Hz), 129.1, 128.9, 128.8, 128.7, 128.6, 128.5, 128.4, 128.3, 117.3 (C-F, ¹ $J_{C-F} = 576.5$ Hz), 67.6, 52.5; IR (ATR) 1754, 1698 cm⁻¹; HRMS (ESI-TOF) m/z calcd for C₂₃H₁₈F₃NO₃Na 436.1131 (M+Na)⁺, found 436.1133.

Methyl N-([1,1'-Biphenyl]-2-yl)-N-(methoxycarbonyl)glycinate **(S2h)**. Compound **S2h** was prepared according to a similar procedure



described for the preparation of **S2a** from **S1a**. Colorless crystal (492.0 mg, 89%), mp 65–66 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.55–7.53 (m, 1H), 7.42–7.40 (m, 2H), 7.39–7.34 (m, 4H), 7.28 (dd, 2H, *J* = 7.2, 1.2 Hz), 4.33 (d, 1H, *J* = 18.0 Hz), 3.69 (s, 3H), 3.65 (s, 3H), 3.35 (d, 1H, *J* = 18.0 Hz); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 170.1, 156.7, 139.4, 139.2, 139.0, 130.8, 130.4, 129.9, 128.8, 128.7, 128.5, 128.4, 128.2, 127.7, 53.4, 52.2, 51.6; IR (ATR) 1754, 1698 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₇H₁₇NO₄Na 322.1050 (M+Na)⁺, found 322.1055.

3-Methyl-2-nitro-(1,1')-biphenyl (S3). K₂CO₃ (1279.8 mg, 9.26 mmol) and Pd(PPh₃)₄ (250 mg) were added to a stirred solution of



3-bromo-2-nitrotoluene (1.00 g, 4.63 mmol) and phenylboronic acid (839.9 mg, 6.94 mmol) in DMF/H₂O = 5:1 (46.0 mL) at reflux under an argon atmosphere. After being stirred at reflux for 16 h, the mixture was treated with 1 M HCl aq. and extracted with ethyl acetate. The extract was washed with 1 M HCl aq. and brine, dried, and concentrated. The concentrate was purified by column chromatography (silica gel, hexane/CH₂Cl₂ = 2:1) to afford **S3** as colorless crystals (990.2 mg, 99%), mp 74–75 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.44–7.39 (m, 4H), 7.36–7.35 (m, 2H), 7.30 (d, 1H, *J* = 7.2 Hz), 7.26 (d, 1H, *J* = 8.4 Hz), 2.39 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 151.0, 136.9, 134.5, 130.4, 130.1, 129.8, 128.9, 128.8, 128.6, 128.2, 17.6; IR (ATR) 1522, 1370 cm⁻¹; HRMS (EI-MS) *m/z* calcd for C₁₃H₁₁NO₂ 213.0790 (M⁺), found 213.0791.

3-Methyl-2-amino-(1,1')biphenyl (S4). S3 (935.5 mg, 4.39 mmol) was dissolved in THF/MeOH = 1:1 (10.0 mL), and 10% palladium



on activated carbon (93.5 mg, 10% w/w) and hydrogen were added and stirred at rt for 19 h. The mixture was filtered, and the filtrate was washed with water and brine, dried, and concentrated under reduced pressure. The concentrate was purified by recrystallization to provide S4 (800.3 mg, 99%), mp 64–65 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.46–7.43 (m, 4H), 7.36–7.34 (m, 1H), 7.07 (d, 1H, *J* = 6.6 Hz), 7.01 (dd, 1H, *J* = 7.8, 1.2 Hz), 6.77 (dd, 1H, *J* = 7.8, 7.8 Hz), 3.74 (br, 2H), 2.23 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 141.7, 140.0, 129.8, 129.4, 129.0, 128.4, 127.7, 127.3, 122.6, 118.3, 18.1; IR (ATR) 3376, 3457 cm⁻¹; HRMS (ESI-TOF) *m/z* calcd for C₁₃H₁₄N 184.1121 (M+H)⁺, found 184.1128.

2,2,2-Trifluoro-N-(3-methyl-[1,1'-biphenyl]-2-yl)acetamide (**S5g**). Compound **S5g** was prepared according to a similar procedure



as described for the preparation of **S1g** from 2-aminobiphenyl. Colorless crystal (285.0 mg, 99%), mp 152–153 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.42–7.35 (m, 3H), 7.33 (d, 1H, *J* = 4.2 Hz), 7.29 (d, 1H, *J* = 7.2 Hz), 7.26–7.24 (m, 2H), 7.22 (dd, 1H, *J* = 7.2, 1.2 Hz), 2.29 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 156.0 (C–F, ²*J*_{C–F} = 37.6 Hz), 139.9, 138.5, 136.4, 130.5, 129.6, 128.8, 128.7, 128.4, 128.1, 116.0 (C–F, ¹*J*_{C–F} = 289.0 Hz), 18.4; IR (ATR) 3253, 1680 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₅H₁₁F₃NO 278.0798 (M–H)⁻, found 278.0795.

Methyl (3-Methyl-[1,1'-biphenyl]-2-yl)carbamate (S5h). Compound S5h was prepared according to a similar procedure as



described for the preparation of **S1a**. Colorless crystal (195.0 mg, 82%), mp 124–125 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.43–7.40 (m, 2H), 7.36–7.33 (m, 2H), 7.32 (dd, 2H, *J* = 8.4, 1.2 Hz), 7.25–7.24 (m, 1H), 7.18–7.17 (m, 1H), 5.95 (br, 1H), 3.67 (s, 3H), 2.35 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 139.8, 139.7, 136.8, 136.7, 132.5, 130.3, 129.0, 128.5, 128.2, 127.5, 127.3, 52.7, 18.6; IR (ATR) 3228, 1706 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₅H₁₆NO₂ 242.1176 (M+H)⁺, found 242.1176.

Methyl N-(Methoxycarbonyl)-N-(3-methyl-[1,1'-biphenyl]-2-yl)glycinate (S6h). Compound S6h was prepared according to a similar



procedure as described for the preparation of **S2a**. Colorless crystal (246.0 mg, 99%), mp 160–162 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.42–7.39 (m, 2H), 7.37–7.34 (m, 1H), 7.31–7.25 (m, 2H), 7.24–7.23 (m, 2H), 7.18 (dd, 1H, *J* = 6.0, 2.4 Hz), 3.91 (d, 1H, *J* = 17.1 Hz), 3.79 (s, 3H), 3.62 (s, 3H), 3.24 (d, 1H, *J* = 17.1 Hz), 2.49 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 169.7, 156.8, 139.7, 139.6, 138.4, 138.3, 130.5, 128.9, 128.5, 128.4, 128.0, 127.7, 53.6, 52.1, 52.0, 18.3; IR (ATR) 1755, 1705 cm⁻¹; HRMS (ESI-TOF) *m/z* calcd for C₁₈H₁₉NO₄Na 336.1206 (M+Na)⁺, found 336.1209.

N-([1,1'-Biphenyl]-2-yl)-4-methylbenzenesulfonamide (S7c). p-Tosyl choloride (270.0 mg, 1.41 mmol) was added to a solution of



2-aminobiphenyl (200.0 mg, 1.18 mmol) in pyridine (10.0 mL) at 0 °C. After stirring at rt for 23 h, the mixture was treated with 1 M HCl aq. and extracted with ethyl acetate. The extract was washed with 1 M HCl aq. and extracted with ethyl acetate. The extract was washed with 1 M HCl aq. and extracted with ethyl acetate. The extract was washed with 1 M HCl aq. and extracted with ethyl acetate. The extract was washed with 1 M HCl aq. and extracted with ethyl acetate. The extract was washed with 1 M HCl aq. and extracted with ethyl acetate. The extract was washed with 1 M HCl aq. and extracted with ethyl acetate. The extract was washed with 1 M HCl aq. and extracted with ethyl acetate. The extract was washed with 1 M HCl aq. and extracted with ethyl acetate. The extract was washed with 1 M HCl aq. and extracted with ethyl acetate. The extract was washed with 1 M HCl aq. and extracted with ethyl acetate. The extract was washed with 1 M HCl aq. and extracted with ethyl acetate. The extract was washed with 1 M HCl aq. and extracted with ethyl acetate. The extract was washed with 1 M HCl aq. and extracted with ethyl acetate. The extract was washed with 1 M HCl aq. and extracted with ethyl acetate. The extract definition of the extract the concentrate was purified by column chromatography (silica gel, hexane/EtOAc = 4:1) to afford S7c as colorless crystals (243.1 mg, 64%), mp 92–93 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.71(d, 1H, *J* = 8.4 Hz), 7.47 (d, 2H, *J* = 8.4 Hz), 7.38–7.31 (m, 4H), 7.19 (d, 2H, *J* = 7.2, 1.8 Hz), 6.58 (br, 1H), 2.40 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 144.0, 137.4, 136.3, 134.0,

133.9, 130.4, 129.7, 129.2, 129.0, 128.8, 128.2, 127.3, 125.0, 121.5, 21.7; IR (ATR) 3245, 1328, 1158 cm⁻¹; HRMS (ESI-TOF) m/z calcd for C₁₉H₁₇NO₂SNa 346.0872 (M+Na)⁺, found 346.0872.

N-([1,1'-Biphenyl]-2-yl)methanesulfonamide (**S7d**). Compound **S7d** was prepared according to a similar procedure as described for



the preparation of **S7c** from 2-aminobiphenyl. Colorless crystal (225.0 mg, 91%), mp 62–63 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.67 (d, 1H, *J* = 7.8 Hz), 7.50 (dd, 2H, *J* = 7.2, 7.2 Hz), 7.44 (ddd, 1H, *J* = 7.8, 7.8, 1.8 Hz), 7.39 (ddd, 1H, *J* = 8.4, 8.4, 1.8 Hz), 7.33–7.32 (m, 2H), 7.28 (dd, 1H, *J* = 7.2, 1.8 Hz), 7.23 (ddd, 1H, *J* = 7.8, 7.8, 1.8 Hz), 6.49 (br, 1H), 2.87 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 137.5, 134.1, 133.4, 130.9, 129.6, 129.1, 128.6, 125.0, 120.1, 39.8; IR (ATR) 3252, 1317, 1144 cm⁻¹; HRMS (ESI-TOF) *m/z* calcd for C₁₃H₁₂NO₂S 246.0594 (M–H)⁻, found 246.0600.

N-([1,1'-Biphenyl]-2-yl)-2-nitrobenzenesulfonamide (**S7e**). Compound **S7e** was prepared according to a similar procedure as



described for the preparation of **S7c** from 2-aminobiphenyl. Colorless crystal (284.5 mg, 80%), mp 101–102 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.75 (dd, 1H, *J* = 7.2, 1.2 Hz), 7.71 (d, 2H, *J* = 8.4 Hz), 7.67 (ddd, 1H, *J* = 7.8, 7.8, 1.2 Hz), 7.65 (br, 1H), 7.59 (ddd, 1H, *J* = 7.8, 7.8, 1.8 Hz), 7.40 (ddd, 1H, *J* = 7.8, 7.8, 1.2 Hz), 7.28–7.27 (m, 1H), 7.25–7.21 (m, 3H), 7.13 (dd, 1H, *J* = 7.8, 1.8 Hz), 6.86 (dd, 2H, *J* = 8.4, 1.8 Hz); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 147.6, 137.5, 136.4, 133.6, 133.4, 133.1, 132.7, 131.0, 130.4, 129.0, 128.9, 128.7, 128.1, 126.4, 125.8, 125.3; IR (ATR) 3326, 1533, 1391, 1359, 1176 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₈H₁₄N₂O₄SNa 377.0566 (M+Na)⁺, found 377.0567.

N-([1,1'-Biphenyl]-2-yl)-4-nitrobenzenesulfonamide (**S7f**). Compound **S7f** was prepared according to a similar procedure as described



for the preparation of **S7c** from 2-aminobiphenyl. Colorless crystal (329.6 mg, 93%), mp 143–144 °C: ¹H NMR (600 MHz, CDCl₃) δ 8.17 (dt, 2H, *J* = 8.4, 1.8, Hz), 7.71 (dd, 1H, *J* = 7.8, 1.2 Hz), 7.64 (dt, 2H, *J* = 9.0, 1.8, Hz), 7.40–7.37 (m, 2H), 7.33 (dd, 2H, *J* = 7.2, 7.2 Hz), 7.24 (ddd, 1H, *J* = 7.8, 7.8, 1.2 Hz), 7,14 (dd, 1H, *J* = 7.8, 1.8 Hz), 6.82 (dd, 2H, *J* = 7.2, 1.8 Hz), 6.80 (br, 1H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 150.3, 144.7, 137.1, 135.1, 132.5, 130.6, 129.4, 129.1, 128.7, 128.5, 126.4, 124.2, 123.1; IR (ATR) 3267, 1523, 1400, 1347, 1165 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₈H₁₃N₂O₄S 353.0602 (M–H)⁻, found 353.0600.

Methyl N-([1,1'-Biphenyl]-2-yl)-N-tosylglycinate (S8c). Sodium hydride (60% oil) (80.0 mg, 2.01 mmol) was added to a stirred



solution of S7c (218.0 mg, 0.67 mmol) in DMF (5.0 mL) at 0 °C under an argon atmosphere. The mixture was stirred at rt for 20 min, then cooled to 0 °C and treated with methyl bromoacetate (93.0 μ L, 1.00 mmol). After stirring at rt for 1 h, the mixture was treated with 1 M HCl aq. and extracted with ethyl acetate. The extract was washed with 1 $\bar{\rm M}$ HCl aq., 1 M NaHCO3 aq., and brine, dried, and concentrated. The concentrate was purified by column chromatography (silica gel, hexane/EtOAc = 4:1) to afford S8c as colorless crystal (212.0 mg, 80%), mp 103-104 °C: ¹H NMR (600 MHz, $CDCl_3$) δ 7.66 (ddd, 2H, J = 8.4, 2.4, 1.8 Hz), 7.39–7.35 (m, 7H), 7.32 (dd, 1H, J = 7.8, 1.8 Hz), 7.29 (dd, 2H, J = 8.4, 1.8 Hz), 7.27-7.26 (m, 1H), 3.98 (br, 2H), 3.52 (s, 3H), 2.46 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 169.5, 143.8, 141.4, 138.8, 138.0, 137.3, 131.8, 130.6, 129.5, 129.2, 128.8, 128.5, 128.2, 128.1, 127.8, 52.1, 52.1, 21.8; IR (ATR) 1740, 1332, 1155 cm⁻¹; HRMS (ESI-TOF) *m/z* calcd for C₂₂H₂₁NO₄SNa 418.1084 (M+Na)⁺, found 418.1098.

Methyl N-[[1,1'-Biphenyl]-2-yl)-N-(methylsulfonyl)glycinate (**S8d**). Compound **S8d** was prepared according to a similar procedure



as described for the preparation of **S8c** from **S7c**. Colorless crystal (280.0 mg, 99%), mp 110–111 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.66 (dd, 1H, *J* = 7.8, 1.2 Hz), 7.53 (d, 2H, *J* = 6.6 Hz), 7.45 (dd, 2H, *J* = 7.2, 7.2 Hz), 7.44–7.38 (m, 4H), 3.96 (br, 2H), 3.66 (s, 3H), 3.23 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 170.4, 141.7, 138.7, 137.6, 132.0, 129.8, 129.2, 129.1, 128.6, 128.0, 52.4, 52.3, 42.7; IR (ATR) 1753, 1330, 1548 cm⁻¹; HRMS (ESI-TOF) *m/z* calcd for C₁₆H₁₇NO₄SNa 342.0771 (M+Na)⁺, found 342.0776.

Methyl N-([1,1'-Biphenyl]-2-yl)-N-([2-nitrophenyl]sulfonyl)glycinate (S8e). Compound S8e was prepared according to a similar



procedure as described for the preparation of **S8c** from **S7c**. Colorless crystal (303.0 mg, 96%), mp 122–123 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.90 (dd, 1H, *J* = 7.8, 1.8 Hz), 7.78 (dd, 1H, *J* = 7.8, 1.2 Hz), 7.69 (ddd, 1H, *J* = 7.2, 7.2, 1.2 Hz), 7.65 (ddd, 1H, *J* = 7.8, 7.8, 1.2 Hz), 7.56 (ddd, 1H, *J* = 7.2, 7.2, 1.8 Hz), 7.31–7.27 (m, 4H), 7.18–7.17 (m, 2H), 4.20 (br, 2H), 3,63 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 169.7, 148.1, 141.9, 138.4, 136.9, 134.3, 133.7, 131.9, 131.9, 131.8, 131.7, 129.4, 128.8, 128.5, 128.4, 127.7, 124.5, 53.3, 52.3; IR (ATR) 1755, 1547, 1373, 1361, 1170 cm⁻¹; HRMS (ESI-TOF) *m/z* calcd for C₂₁H₁₈N₂O₆SNa 499.0778 (M+Na)⁺, found 499.0785.

Methyl N-([1,1'-Biphenyl]-2-yl)-N-([4-nitrophenyl]sulfonyl)glycinate (S8f). Compound S8f was prepared according to a similar



procedure as described for the preparation of **S8c** from **S7c**. Colorless crystal (334.0 mg, 91%), mp 149–150 °C: ¹H NMR (600 MHz, CDCl₃) δ 8.30 (dt, 2H, *J* = 9.0, 2.4 Hz), 7.92 (dt, 2H, *J* = 9.0, 1.8 Hz), 7.44–7.39 (m, 6H), 7.36 (d, 1H, *J* = 7.2 Hz), 7.30 (dd, 2H, *J* = 4.8, 1.8 Hz), 4.13 (br, 2H), 3.59 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 169.3, 150.2, 146.4, 141.8, 138.4, 136.6, 132.2, 130.4, 129.6, 129.0, 128.6, 128.5, 128.0, 124.0, 52.9, 52.4; IR (ATR) 1760, 1525,

1341, 1313, 1163 cm⁻¹; HRMS (ESI-TOF) m/z calcd for $C_{21}H_{19}N_2O_6S$ 427.0958 (M+H)⁺, found 427.0973.

4-Methyl-N-(3-methyl-[1,1'-biphenyl]-2-yl)benzenesulfonamide (**S9c**). Compound **S9c** was prepared according to a similar procedure



as described for the preparation of S7c from 2-aminobiphenyl. Colorless crystal (303.9 mg, 90%), mp 114–116 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.29 (d, 1H, *J* = 7.8 Hz), 7.22–7.18 (m, 2H), 7.14 (dd, 2H, *J* = 7.2, 7.2 Hz), 7.09 (d, 2H, *J* = 7.8 Hz), 6.97 (d, 3H, *J* = 7.8 Hz), 6.78 (dd, 2H, *J* = 7.2, 1.2 Hz), 6.52 (br, 1H), 2.56 (s, 3H), 2.38 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 143.0, 140.6, 139.1, 139.0, 136.7, 131.2, 131.1, 129.5, 128.5, 128.4, 127.6, 127.0, 21.6, 20.1; IR (ATR) 3294, 1331, 1162 cm⁻¹; HRMS (ESI-TOF) *m/z* calcd for C₂₀H₁₉NO₂SNa 360.1029 (M+Na)⁺, found 360.1029.

N-(3-Methyl-[1,1⁷-biphenyl]-2-yl)methanesulfonamide (S9d). Compound S9d was prepared according to a similar procedure as



described for the preparation of S7c from 2-aminobiphenyl. Colorless crystal (216.5 mg, 83%), mp 95–96 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.47–7.44 (m, 2H), 7.41–7.36 (m, 3H), 7.32–7.29 (m, 2H), 7.22–7.19 (m, 1H), 6.05 (br, 1H), 2.53 (s, 3H), 2.21 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 141.0, 139.9, 139.0, 131.7, 130.9, 129.7, 128.8, 128.7, 128.3, 127.8, 41.2, 19.8; IR (ATR) 3244, 1314, 1145 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₄H₁₅NO₂SNa 284.0716 (M+Na)⁺, found 284.0719.

N-(3-Methyl-[1,1'-biphenyl]-2-yl)-2-nitrobenzenesulfonamide (**S9e**). Compound **S9e** was prepared according to a similar procedure



as described for the preparation of **S7c** from 2-aminobiphenyl. Colorless crystal (206.6 mg, 47%), mp 135–137 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.66 (dd, 1H, *J* = 8.4, 1.2 Hz), 7.59–7.54 (m, 3H), 7.51 (ddd, 1H, *J* = 7.8, 7.8, 1.2 Hz), 7.34 (d, 1H, 7.2 Hz), 7.29–7.26 (m, 1H), 7.03–6.97 (m, 3H), 6.91 (dd, 2H, 7.8, 2.4 Hz), 2.61 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 146.7, 140.9, 140.0, 138.9, 135.2, 133.1, 132.9, 131.5, 130.9, 130.6, 128.8, 128.5, 128.3, 128.2, 127.1, 126.1, 20.0; IR (ATR) 3386, 1532, 1385, 1328, 1162 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₂₉H₁₆N₂O₄SNa 391.0723 (M +Na)⁺, found 391.0723.

N-(3-Methyl-[1,1'-biphenyl]-2-yl)-4-nitrobenzenesulfonamide (**S9f**). Compound **S9f** was prepared according to a similar procedure



as described for the preparation of **S7c** from 2-aminobiphenyl. Colorless crystal (315.7 mg, 86%), mp 148–151 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.95 (dd, 2H, *J* = 8.4, 1.2 Hz), 7.38 (dd, 2H, *J* = 8.4, 1.8 Hz), 7.34 (d, 1H, *J* = 8.4 Hz), 7.28 (dd, 1H, *J* = 8.4, 8.4 Hz), 7.18 (dd, 1H, *J* = 7.8, 7.8 Hz), 7.09 (dd, 2H, *J* = 7.2, 7.2 Hz), 7.00 (d, 1H, *J*

= 7.8 Hz), 6.80 (d, 2H, J = 8.4 Hz), 6.67 (br, 1H), 2.62 (s, 3H); $^{13}C{1H}$ NMR (150 MHz, CDCl₃) δ 149.8, 143.3, 140.7, 139.8, 138.9, 131.3, 130.0, 128.9, 128.7, 128.6, 128.5, 128.1, 127.3, 124.0, 20.1; IR (ATR) 3259, 1525, 1351, 1310, 1154 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₉H₁₅N₂O₄S 367.0758 (M-H)⁻, found 367.0750.

Methyl N-(3-Methyl-[1,1'-biphenyl]-2-yl)-N-tosylglycinate (S10c). Compound S10c was prepared according to a similar



procedure as described for the preparation of **S8c** from **S7c**. Colorless crystal (234.1 mg, 66%), mp 118–120 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.57 (d, 2H, *J* = 8.4 Hz), 7.33–7.30 (m, 1H), 7.28–7.25 (m, 6H), 7.21 (d, 2H, *J* = 8.2 Hz), 7.08–7.06 (m, 1H), 4.17 (d, 1H, *J* = 17.2 Hz), 3.81 (d, 1H, *J* = 17.2 Hz), 3.54 (s, 3H), 2.43 (s, 3H), 2.37 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 169.2, 143.6, 142.9, 140.2, 139.9, 137.5, 137.4, 131.2, 129.9, 129.6, 129.4, 128.3, 128.2, 127.9, 127.5, 53.2, 52.1, 21.7, 20.3; IR (ATR) 1766, 1335, 1158 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₂₃H₂₄NO₄S 410.1421 (M+H)⁺, found 410.1424.

Methyl N-(3-Methyl-[1,1'-biphenyl]-2-yl)-N-(methylsulfonyl)glycinate (S10d). Compound S10d was prepared according to a



similar procedure as described for the preparation of **S8c** from **S7c**. Colorless crystal (243.4 mg, 91%), mp 108–109 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.44–7.35 (m, 5H), 7.30–7.27 (m, 2H), 7.15–7.13 (m, 1H), 4.31 (d, 1H, *J* = 18.0 Hz), 3.97 (d, 1H, *J* = 18.0 Hz), 3.68 (s, 3H), 2.80 (s, 3H), 2.55 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 169.6, 142.7, 140.0, 139.2, 138.6, 131.3, 129.8, 129.6, 128.5, 128.2, 127.8, 53.5, 52.3, 42.4, 19.9; IR (ATR) 1756, 1327, 1139 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₇H₁₉NO₄SNa 356.0927 (M +Na)⁺, found 356.0927.

Methyl N-(3-Methyl-[1,1'-biphenyl]-2-yl)-N-([2-nitrophenyl]sulfonyl)glycinate (S10e). Compound S10e was prepared according



to a similar procedure as described for the preparation of **S8c** from **S7c**. Colorless crystal (332.0 mg, 84%), mp 138–139 °C: ¹H NMR (600 MHz, CDCl₃) δ 7.73 (dd, 1H, *J* = 9.0, 1.8 Hz), 7.65 (ddd, 1H, *J* = 7.6, 7.6, 1.2 Hz), 7.54–7.51 (m, 2H), 7.34–7.27 (m, 3H), 7.23 (dd, 2H, *J* = 7.6, 7.6 Hz), 7.17 (d, 2H, *J* = 6.6 Hz), 7.07–7.04 (m, 1H), 4.48 (d, 1H, *J* = 18.0 Hz), 4.08 (d, 1H, *J* = 18.0 Hz), 3.64 (s, 3H), 2.45 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 169.1, 148.5, 143.4, 140.2, 139.7, 136.5, 134.0, 133.7, 132.0, 131.6, 130.2, 129.5, 128.8, 128.0, 127.6, 124.2, 54.4, 52.3, 20.3; IR (ATR) 1771, 1548, 1374, 1346, 1199 cm⁻¹; HRMS (ESI-TOF) *m/z* calcd for C₂₂H₂₀N₂O₆SNa 463.0934 (M+Na)⁺, found 463.0935.

Methyl N-(3-Methyl-[1,1'-biphenyl]-2-yl)-N-([4-nitrophenyl)sulfonyl)glycinate (**S10f**). Compound **S10f** was prepared according to a similar procedure as described for the preparation of **S8c** from **S7c**. Colorless crystal (324.4 mg, 87%), mp 153–156 °C: ¹H NMR (600 MHz, CDCl₃) δ 8.16 (dd, 2H, J = 8.4, 2.4 Hz), 7.80 (dd, 2H, J =



9.0, 1.8 Hz), 7.32–7.27 (m, 3H), 7.24 (dd, 2H, J = 7.2, 7.2 Hz), 7.19 (dd, 2H, J = 6.6, 1.8 Hz), 7.09 (dd, 1H, J = 7.2, 1.8 Hz), 4.27 (d, 1H, J = 17.4 Hz), 4.22 (d, 1H, J = 17.4 Hz), 3.65 (s, 3H), 2.36 (s, 3H); ¹³C{1H} NMR (150 MHz, CDCl₃) δ 168.8, 150.0, 145.9, 143.1, 139.8, 139.5, 136.9, 131.5, 130.2, 129.5, 129.0, 128.0, 127.6, 123.7, 54.3, 52.4, 20.0; IR (ATR) 1759, 1524, 1349, 1314, 1158 cm⁻¹; HRMS (ESI-TOF) m/z calcd for C₂₂H₂₀N₂O₆SNa 463.0934 (M +Na)⁺, found 463.0934.

Measurement of the Blocking Activity on the Voltage-Gated Potassium Channel Kv1.3. The assays were performed under the conditions described below. The parameters measured the maximum outward current evoked on stepping to 0 mV from the holding potential. The peak current amplitude was calculated before and after compound addition, and the amount of block was assessed by dividing the test compound current amplitude by the control current amplitude. Test compounds are the mean hKv1.3 current amplitude collected in the presence of test compound at each concentration, and the control is the mean hKv1.3 current amplitude collected for the last 15 s of the control. All data were filtered for seal quality, seal drop, and current amplitude.

ASSOCIATED CONTENT

1 Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.joc.1c00594.

Reaction schemes to prepare 1A-h and 1Bc-h; ¹H NMR spectra of IBg and IBh; Chiral HPLC charts of IBg, IBh, IIBc, IIBd, IIBe, IIBf; Stereochemical stability of the enantiomers of IBg, IBh, IIBc, IIBd, IIBe, IIBf; NOE spectrum of IAa; ORTEP drawing of IIBc; DFT calculation study; ¹H-, ¹³C-, and 2D-NMR (COSY, HMBC for IAa) spectra (PDF)

Accession Codes

CCDC 2057747 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.

AUTHOR INFORMATION

Corresponding Author

Hideyo Takahashi – Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda-shi, Chiba 278-8510, Japan; orcid.org/0000-0001-5965-3987; Email: hidetak@rs.tus.ac.jp

Authors

- Takuya Namba Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda-shi, Chiba 278-8510, Japan
 Mayuno Hotta – Faculty of Pharmaceutical Sciences, Tokyo
- University of Science, Noda-shi, Chiba 278-8510, Japan
- Hidetsugu Tabata Faculty of Pharma Sciences, Teikyo University, Itabashi-ku, Tokyo 173-8605, Japan
- Kosho Makino Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda-shi, Chiba 278-8510, Japan

pubs.acs.org/joc

Tetsuta Oshitari – Faculty of Pharma Sciences, Teikyo University, Itabashi-ku, Tokyo 173-8605, Japan Hideaki Natsugari – Graduate School of Pharmaceutical Science, The University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan; orcid.org/0000-0002-6442-1598

Complete contact information is available at: https://pubs.acs.org/10.1021/acs.joc.1c00594

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This work was supported in part by a Grant-in-Aid for Scientific Research (C) (19K06980) from the Japan Society for the Promotion of Science. H.T. is grateful for financial support from the Hoansha Foundation.

REFERENCES

(1) For recent review articles on medium-ring benzo-fused nitrogenous heterocycles, see: (a) Ryan, J. H.; Hyland, C.; Meyer, A. G.; Smith, J. A.; Yin, J. X. Chapter 7 - Seven-Membered Rings. *Prog. Heterocycl. Chem.* **2012**, *24*, 493–536. (b) Ramig, K. Stereodynamic properties of medium-ring benzo-fused nitrogenous heterocycles: benzodiazepines, benzazepines, benzazocines, and benzazonines. *Tetrahedron* **2013**, *69*, 10783–10795.

(2) (a) Natsugari, H.; Ikeura, Y.; Kamo, I.; Ishimaru, T.; Ishichi, Y.; Fujishima, A.; Tanaka, T.; Kasahara, F.; Kawada, M.; Doi, T. J. Med. Chem. 1999, 42, 3982. (b) Tabata, H.; Nakagomi, J.; Morizono, D.; Oshitari, T.; Takahashi, H.; Natsugari, H. Atropisomerism in the vaptan class of vasopressin receptor ligands: The active conformation recognized by the receptor. Angew. Chem., Int. Ed. 2011, 50, 3075-3079. (c) Tabata, H.; Wada, N.; Takada, Y.; Nakagomi, J.; Miike, T.; Shirahase, H.; Oshitari, T.; Takahashi, H.; Natsugari, H. Active conformation of seven-membered-ring benzolactams as new ACAT inhibitors: Latent chirality at N5 in the 1,5-benzodiazepin-2-one nucleus. Chem. - Eur. J. 2012, 18, 1572-1576. (d) Yoneda, T.; Tabata, H.; Tasaka, T.; Oshitari, T.; Takahashi, H.; Natsugari, H. N-Benzoyl-1,5-benzothiazepine and its S-oxide as vasopressin receptor ligands: Insight into the active stereochemistry around the seven-membered ring. J. Med. Chem. 2015, 58, 3268-3273. (e) Tabata, H.; Yoneda, T.; Oshitari, T.; Takahashi, H.; Natsugari, H. Tolvaptan-type vasopressin receptor ligands: Important role of axial chirality in the active form. J. Med. Chem. 2017, 60, 4503-4509.

(3) For general review articles on the atropisomerism in drug discovery, see: (a) Glunz, P. W. Recent encounters with atropisomerism in drug discovery. *Bioorg. Med. Chem. Lett.* 2018, 28, 53-60. (b) Kumarasamy, E.; Raghunathan, R.; Sibi, M. P.; Sivaguru, J. Nonbiaryl and heterobiaryl atropisomers: Molecular templates with promise for atropselective chemical transformations. *Chem. Rev.* 2015, *115*, 11239-11300. (c) LaPlante, S. R.; Fader, L. D.; Fandrick, K. R.; Fandrick, D. R.; Hucke, O.; Kemper, R.; Miller, S. P. F.; Edwards, P. J. Assessing atropisomer axial chirality in drug discovery and development. *J. Med. Chem.* 2011, *54*, 7005-7022. (d) Clayden, J.; Moran, W. J.; Edwards, P. J.; LaPlante, S. R. The challenge of atropisomerism in drug discovery. *Angew. Chem., Int. Ed.* 2009, *48*, 6398-6401.

(4) Pegoraro, S.; Lang, M.; Dreker, T.; Kraus, J.; Hamm, S.; Meere, C.; Feurle, J.; Tasler, S.; Prütting, S.; Kuras, Z.; Visan, V.; Grissmer, S. Inhibitors of potassium channels Kv1.3 and IK-1 as immunosuppressants. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 2299–2304.

(5) (a) Jensen, B. S.; Strobaek, D.; Olesen, S.-P.; Christophersen, P. The Ca²⁺-activated K⁺ channel of intermediate conductance: a molecular target for novel treatments? *Curr. Drug Targets* **2001**, *2*, 401–422. (b) Jensen, B. S.; Hertz, M.; Christophersen, P.; Madsen, L. S. The Ca²⁺-activated K⁺ channel of intermediate conductance: a possible target for immune suppression. *Expert Opin. Ther. Targets* **2002**, *6*, 623–636.

(6) The terms a S and a R (chiral axis nomenclature) correspond to P and M (helix nomenclature), respectively.

(7) (a) Yoneda, T.; Tabata, H.; Nakagomi, J.; Tasaka, T.; Oshitari, T.; Takahashi, H.; Natsugari, H. N-Benzoyl- and N-sulfonyl-1,5benzodiazepines: Comparison of their atropisomeric and conformational properties. J. Org. Chem. 2014, 79, 5717–5727. (b) Tabata, H.; Tsuji, Y.; Yoneda, T.; Tasaka, T.; Oshitari, T.; Takahashi, H.; Natsugari, H. Atropisomerism in the 2,3,4,5-tetrahydro-1H-1,5benzodiazepine nucleus: Effects of central chirality at C3 on the Nmesylation. Synlett 2018, 29, 2141–2146. (c) Tabata, H.; Murai, K.; Funaki, K.; Takemae, C.; Tasaka, T.; Oshitari, T.; Takahashi, H.; Natsugari, H. Atropisomeric and conformational properties of 6Nbenzoyl and 6N-p-tosyl-1,6-benzodiazocines: Comparison with those of 1,5 with those of 1,5-benzodiazepines. Heterocycles 2019, 99, 566– 581.

(8) (a) Boyd, G. V. 5-Oxazolonium perchlorates from α -acylaminoacids. *Chem. Commun.* **1968**, *0*, 1410–1412. (b) Boyd, G. V.; Wright, P. H. Cyclisation of α -acylamino-acids in the presence of perchloric acid to give 5-oxo Δ 2-oxazolinium perchlorates. *J. Chem. Soc., Perkin Trans. 1* **1972**, 909–913.

(9) (a) Paterson, W.; Proctor, G. R. Azabenzocycloheptenones. Part. IV. An azadibenzotropone. J. Chem. Soc. 1962, 3468-3472.
(b) Proctor, G. R. Azabenzocycloheptenones. Part III. 2,3,4,5-Tetrahydro-5-oxo-1-toluene-p-sulphonylbenz[b]azepine. J. Chem. Soc. 1961, 3989-3994.

(10) For the preparation of 1Aa-h and 1Bc-h, see the Supporting Information, in which the reaction schemes including compound number are described. The characterization of the intermediates S1a, S1b, S1g, S1h, S2a, S2b, S2g, S2h, S3, S4, S5g, S5h, S6h, S7c, S7d, S7e, S7f, S8c, S8d, S8e, S8f, S9c, S9d, S9e, S9f, S10c, S10d, S10e, and S10f are described in the Experimental Section.

(11) (a) Tabata, H.; Akiba, K.; Lee, S.; Takahashi, H.; Natsugari, H. Atropisomeric properties of the dibenzo [b,d] azepin-6-one nucleus. Org. Lett. 2008, 10, 4871–4874. (b) Tabata, H.; Suzuki, H.; Akiba, K.; Takahashi, H.; Natsugari, H. Atropisomeric properties of 7-, 8-, and 9-membered-ring dibenzolactams: Conformation, thermal stability, and chemical reactivity. J. Org. Chem. 2010, 75, 5984–5993.

(12) (a) Hassner, A.; Amit, B. Conformation of medium sized ring amines. NMR studies of *N*-acyl derivatives. *Tetrahedron Lett.* **1977**, *18*, 3023–3026. (b) Qadir, M.; Cobb, J.; Sheldrake, P. W.; Whittall, N.; White, A. J. P.; Hii, K. K.; Horton, P. N.; Hursthouse, M. B. Conformation analyses, dynamic behavior and amide bond distortions of medium-sized heterocycles. 1. Partially and fully reduced 1-benzazepines. J. Org. Chem. **2005**, *70*, 1545–1551.

(13) For predicting free energy in solution, the polarizable continuum model was used, see: Cancès, E.; Mennucci, B.; Tomasi, J. A new integral equation formalism for the polarizable continuum model: Theoretical background and applications to isotropic and anisotropic dielectrics. J. Chem. Phys. **1997**, 107, 3032–3041.

(14) For determination of ΔG^{\ddagger} values, see: Petit, M.; Lapierre, A. J. B.; Curran, D. P. Relaying asymmetry of transient atropisomers of *o*-iodoanilides by radical cyclizations. *J. Am. Chem. Soc.* **2005**, *127*, 14994–14995.

(15) In the $>N-SO_2$ moiety of the N-tosyl derivative (1B), the nitrogen atom possesses an sp²-like nature (the sum of angles around the nitrogen atom is *ca.* 360°), N–S has the double-bond character, and thus the >N-S part forms a plane. The axis between the two planes (i.e., benzene and the >N-S part), which are approximately orthogonally oriented, causes the chirality.

(16) Alonso, D. N.; P-Torralba, M.; Claramunt, R. M.; Torralba, M. C.; D-Martinez, P.; Alkorta, I.; Elguero, J.; Roussel, C. Regiospecific synthesis and structural studies of 3,5-dihydro-4*H*-pyrido[2,3-*b*][1,4]-diazepin-4-ones and comparison with 1,3-dihydro-2H-benzo[*b*][1,4]-diazepin-2-ones. ACS Omega **2020**, 5, 25408–25422.

(17) N-(1,1')-Biphenyl-2-yl-glycine derivatives **1A** and **1B** have axial chirality, which is under consideration. For a related paper, see: (a) Lu, S.; Ng, S. V. H.; Lovato, K.; Ong, J.-Y.; Poh, S. B.; Ng, X. Q.; Kurti, L.; Zhao, Y. Practical access to axially chiral sulfonamides and biaryl amino phenols via organocatalytic atroposelective *N*-alkylation.

Nat. Commun. **2019**, *10*, 3061–3070. (b) Kikuchi, Y.; Nakamura, C.; Matsuoka, M.; Asami, R.; Kitagawa, O. Catalytic enantioselective synthesis of N–C axially chiral sulfonamides through chiral palladium-catalyzed *N*-allylation. *J. Org. Chem.* **2019**, *84*, 8112–8120.